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Abstract 
In the recent decade, two strategies in particular have attracted attention due to the prospect of 
significantly improving cancer treatment: Gene silencing therapy and immunotherapy. Both 
strategies work by manipulating endogenous mechanisms and theoretically promise very strong 
effect on the diseased cells and minimal effect on the healthy ones. This thesis regards the 
investigation of important mechanistic aspects of gene silencing mediated by delivery of small 
interfering RNA (siRNA) using synthetic vectors (Project I) as well as the development of a 
delivery platform for targeted immunotherapy (Project II). 
Transfer into the clinic of therapies based on gene silencing by siRNA delivered by synthetic 
vectors has yet to happen. A major reason is the lack of efficiency in the delivery process, partly 
due to insufficient understanding of cellular uptake and processing of the siRNA-containing 
particles. 
Project I aims to provide new mechanistic understanding of intracellular processing and vector 
interaction with target cells by investigating siRNA delivery using branched polyethyleneimine 
(bPEI), which is a well-known synthetic vector for DNA delivery, and comparing the properties of 
bPEI with a lipid derivative thereof (DOPE-PEI).  
We demonstrate mechanistic differences between the bPEI conjugate and conventional bPEI 
with respect to siRNA condensation and intracellular processing and also show that lipid 
conjugation of bPEI results in markedly different formulation requirements compared to the 
conventional PEIs. However, lipid conjugation did not sufficiently reduce the inherent toxicity 
associated with high molecular weight PEI, and lipid conjugation of bPEI did also not change the 
ability of bPEI to affect lysosomal pH as a function of time. 
In contrast to gene silencing therapy, cancer immunotherapy is starting to produce positive 
results in the clinic. A major target in cancer immunotherapy is the immunosuppressive tumor 
microenvironment generated directly or indirectly by the tumor. Tumor tissues have been 
shown to be heavily infiltrated by macrophages and DCs but due to the immunosuppressive 
environment they frequently adopt an in-active or tumor-promoting phenotype. 
Project II describes the development of a platform which enables the highly specific targeting of 
monocytes and DCs in the bloodstream. Using this platform to deliver a TLR7 agonist, we were 
able to demonstrate activation of the targeted cells and increased potency of the agonist. While 
the described platform targets selected immune cells in the blood and not in itself targets the 
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tumor tissue, we believe that because tumor associated inflammation has been shown to recruit 
monocytes and DCs to the tumor tissues, our strategy could be an elegant and efficient way of 
providing activated monocytes, monocyte-derived macrophages, and DCs to the tumor site. If 
the duration of cytokine secretory activity extends post-extravasation, this will not only provide 
activated innate immune cells to the tumor site, but may also contribute to the re-polarization of 
the tumor microenvironment thereby promoting antitumor immunity. 
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Dansk resumé 
To eksperimentelle cancerbehandlingsstrategier har fået særlig meget opmærksomhed inden for 
det sidste årti: Knockdown genterapi og immunterapi. Begge fungerer via manipulation af 
endogene systemer og begge lover i teorien meget høj og meget specifik effekt på syg-
domsramte celler. Denne afhandling omfatter en undersøgelse af vigtige mekanistiske aspekter 
af knockdown terapi baseret på small interfering RNA (siRNA) leveret af non-virale vektorer 
(Projekt I), samt design og undersøgelse af et system til målrettet immunterapi (Projekt II) 
Bred klinisk brug af siRNA-baseret genterapi leveret af syntetiske vektorer er endnu urealistisk. 
En vigtig grund er ineffektiv levering af siRNA til de sygdomsramte celler, til dels på grund af 
mangelfuld viden om cellernes internalisering og intracellulære behandling af siRNA partiklerne. 
Projekt I søger at forbedre forståelsen af cellernes interaktion med vektorerne. Vi undersøgte 
siRNA-medieret knockdown med forgrenet polyethyleneimine (bPEI) og sammenlignede bPEIs 
egenskaber med et lipidkonjugeret derivat af bPEI. Vi viser, at der er forskel på bPEIs og 
lipidkonjugeret bPEIs egenskaber med hensyn til kondensering, og at lipidkonjugering påvirker 
virkemåden og formuleringsparametrene. Endvidere viser vi, at lipidkonjugering ikke i 
tilstrækkelig grad reducerer bPEIs cytotoxicitet eller ændrer bPEIs evne til at påvirke lysosomal 
pH som funktion af tid.  
I modsætning til knockdown terapi, så er immunterapi begyndt at vise positive resultater til 
kræftbehandling. Det immunundertrykkende nærmiljø omkring en tumor er et vigtigt mål inden 
for immunterapi til kræftbehandling, og det er blevet vist, at selvom makrofager og dendritiske 
celler (DC) er stærkt repræsenteret i tumor vævet, så antager de ofte en inaktiv eller direkte 
immunundertrykkende fænotype. Project II beskriver et system, som muliggør målrettet levering 
til monocytter og DC’er i blodet. Vi brugte systemet til at levere en Toll-like receptor-7 agonist og 
kunne demonstrere aktivering af monocytter og DC’er samt en væsentligt forøget effekt i 
forhold til ikke-målrettet levering. Selvom det beskrevne system er målrettet mod udvalgte 
immunceller i blod og ikke mod (celler i) tumor vævet, mener vi, at fordi monocytter og DC’er 
bliver rekrutteret til tumor vævet via den tumor-associerede inflammation, så kan den 
beskrevne strategi være en måde til dels at opnå aktiverede monocytter, makrofager og DC’er i 
tumor vævet, dels at levere cytokiner med antitumor effekt til tumor nærmiljøet og dermed 
bidrage til at polarisere tumor vævet i en retning, der favoriserer tumor eliminering. 
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Introduction 
 
Introduction 
Cancer is a leading cause of mortality in the world, counting 14 million diagnosed adults and 8.2 
million fatal outcomes in 20121. Consequently, there is a continued search for improved 
strategies in cancer treatment. The current types of treatment are often divided into the 
following main categories: Surgery, radiotherapy, chemotherapy, and biological therapies. 
Biological therapies are variously defined as a. therapies that stimulate the body’s own healing 
mechanism or use biologics (e.g. gene therapy or antibody therapy), or b. therapies that arrest 
or regress cancer growth through interference with biological processes (e.g. inhibition of 
angiogenesis). Regardless of the definition, biotherapies are thus different from 
chemotherapeutic drugs that directly kill malignant cells through cytotoxicity. 
While surgery has proven efficient in treating some cancers, it is clearly limited to localized and 
early-stage cancers, and cancers with limited metastatic activity. The current view is that no 
tumors are inherently non-metastatic2, so most therapeutic strategies include some form of 
chemotherapy or biological therapy even when complete removal of the tumor is deemed 
feasible.  
With very few exceptions, current chemo- and biotherapeutics do not employ any mechanisms 
to ensure tissue- or cell-specific accumulation of the active pharmaceutical ingredients (API)3. 
Whereas biotherapeutics typically target biological parameters, which afford some level of 
functional differentiation between healthy and malignant cells, the mode of action of traditional 
chemotherapeutics is non-specific and results in killing of all (rapidly) dividing cells primarily 
through interference with DNA management (synthesis, structural maintenance, repair or 
replication). One example of a biotherapy with some level of specificity for tumor cells, is breast 
cancer treatment with Trastuzumab (a humanized monoclonal antibody (Ab) against the 
HER2/neu receptor), which bases its discrimination on the relative (but not exclusive) 
overexpression of the target antigen in ≈25% of breast cancers4. 
The lack of targeted delivery of chemo- and biotherapeutics has several undesirable 
consequences. Usually, the API becomes distributed quite evenly within the body, proportionally 
to the regional blood flow, and has to cross many biological barriers (other organs, cells and 
intracellular compartments). Accordingly, it has ample opportunity to interact with and induce 
side effects in organs, tissues and cells that are not involved in the pathological process. Further, 
the drug has to be administered in large quantities in order to achieve the required therapeutic 
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concentration of the API in the target compartments or tissues (which greatly increase the cost 
of the therapy) and the drug may also become inactivated or degraded en route to the target 
tissue3. Finally, due to insufficient specificity of the drug mode-of-action, the impact on the non-
pathological cells may be quite severe, as in many cases the targeted biological parameter is also 
essential for the non-pathological cells. 
Conversely, the ideal drug employs targeted delivery to ensure minimal impact in non-
pathological tissues, thus minimizing the side effects as well as the administered drug dose, and 
combines this with an effector mechanism, which exclusively causes damage to the malignant 
cells thus ensuring that any interaction between drug and non-pathological cells has minimal 
impact on those cells. 
Through the tremendous advances in areas such as genetics, molecular biology and 
immunology, new opportunities for intervention have emerged, which theoretically promise to 
come closer to the ideal drug principle described above. This thesis regards two of those 
strategies, namely gene knockdown therapy, the subject of Project I, and targeted cancer 
immunotherapy, which is the subject of Project II. The uniting core principle is the manipulation 
of endogenous mechanisms to control and combat disease. 
The molecular machinery involved in gene expression and posttranscriptional regulation has 
extremely high specificity through the principle of base-pairing. Therefore, therapy based on 
RNA interference (RNAi) promises absence of unintended gene knockdown, which - if a suitable 
oncogene is targeted - eliminates API-specific effects on non-cancerous cells. However, the 
challenge of targeted and efficient delivery of the therapeutic small interfering RNAs (siRNAs) 
remains, the more so because unprotected/unmodified siRNA is extremely susceptible to 
degradation in the bloodstream and interstitial space. Project I of this thesis is an investigation of 
non-viral siRNA delivery with one of the most commonly used vector polymers, 
polyethyleneimine (PEI). As lipid conjugation has been pursued as a promising strategy to 
increase the delivery efficiency and/or reduce the cytotoxicity of various polymers, the study 
includes a lipid conjugate of PEI. Using a combination of biophysical characterization and in vitro 
assays, we compare the polymers with respect to the interaction of the siRNA-containing 
particles with the target cells; how crucial formulation parameters influence the interplay 
between uptake and gene silencing effect and whether lipid conjugation fundamentally 
improves the potential of PEI as a siRNA delivery agent. 
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The results obtained in the study are presented in section 3 in the form of a manuscript, which 
has been prepared for submission to Biomaterials. Section 1 provides a detailed introduction to 
siRNA based gene therapy and the major obstacles faced by non-viral siRNA delivery. 
Where Project I focuses on cellular interaction, Project II regards true targeted delivery to a 
subset of immune cells with the intent to stimulate the immune system to respond more 
vigorously to the presence of malignant cells. 
As mentioned, a few cancer therapies do employ some level of direct targeting to cancerous 
cells. However, while Trastuzumab therapy is based on an Ab, it is believed to primarily work by 
antagonizing oncogenic pathways and only to a limited extent - if at all - through actual 
stimulation of antitumor immunity4. A more powerful, elegant and potentially more durable 
type of immunotherapy is the sensitization of the immune system to the presence and nature of 
the cancerous cells. Not only will such a strategy leave the actual disease elimination to the 
immune effector cells, which have been matured through millennia of evolution for exactly this 
task, but it will – in its most successful form – lead to the generation of memory cells capable of 
a rapid anti-cancer response should the cancer reappear after initial elimination. In Project II of 
this thesis, we attempt to develop a targeted, liposomal formulation of an immunomodulator 
and investigate whether targeted delivery of the compound to monocytes and dendritic cells 
improves the potency compared to non-targeted delivery. As the targeted cells are all present in 
the bloodstream, the obstacle of extravasation of our delivery vehicle becomes irrelevant, and 
the process of migrating to the diseased tissue to interact with the tumor cells is left to the 
stimulated immune cells working in concert with the vessel endothelia in and around the 
diseased tissues. 
Section 5 of this thesis provides an introduction to cancer immunotherapy, and section 7 
describes the work and results of Project II in the form of a manuscript in preparation for 
submission to Nanomedicine: Nanotechnology, Biology and Medicine. 
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Project I - Non-Viral delivery of siRNA 
 
1 Background 
1.1 Gene therapy - concept, discovery and early development 
Gene therapy is the use of nucleic acids as APIs to treat disease. The aim is to introduce or 
manipulate the expression of the genetic information contained in the targeted cells to influence 
their behavior or survival in a way that can treat or cure disease5. Initially, the vision of gene 
therapy was the treatment of hereditary diseases with genetic basis6; today the scope has  
expanded to include acquired disorders, such as cancer, heart diseases and immunodeficiency 
syndromes6,7. The following sections provide an introduction to gene therapy with emphasis on 
gene silencing. 
The concept of gene therapy arose in the early 1970s when it was found that exogenous DNA 
could be introduced into and subsequently expressed by mammalian cells5. Owing to the 
enormous potential of gene therapy, huge efforts have gone into its development but so far very 
few therapies have been approved. This is mainly due to the lack of efficient and safe delivery of 
the nucleic acid to target cells in vivo8–10. As of 2013, no gene therapies have been approved in 
the US11 or EU for treatment of cancer12, while the first and so far only gene therapy product was 
recommended for approval by the European Medicines Agency (EMA) in July 2012 for treatment 
of lipoprotein lipase deficiency using recombinant lipoprotein lipase in an adeno-associated virus 
vector12. 
1.2 The discovery of gene silencing 
Whereas DNA-based gene therapy attempts to achieve expression of exogenously introduced 
DNA, the objective of gene silencing is to cancel the expression of the targeted gene and 
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eliminate the production of disease-causing proteins which would otherwise arise as a result of 
gene transcription and mRNA translation. 
Specific inhibition of gene expression using DNA-based antisense oligonucleotides (ODN) was 
first described in the late 1970s13,14. Upon transfection into a cell, antisense ODNs were able to 
hybridize to their target mRNA leading to the degradation of the mRNA-DNA hybrid strands. 
However, the crucial breakthrough came when it was discovered that double-stranded RNA 
could silence gene expression in the model organism C. elegans15. This mechanism for post-
transcriptional gene silencing was termed RNA interference (RNAi), and its discovery earned C. 
Mello and A. Fire the Nobel Prize. The observations from C. elegans were rapidly extended to 
mammalian cell lines16 and mice17, after which the biotech community has worked hard to 
translate the technology into a working therapy for the treatment of various diseases, notably 
cancer. 
1.3 RNA interference in the cell 
RNAi is an evolutionarily conserved, post-transcriptional gene-silencing mechanism, which is 
present in most eukaryotic cells and regulates cellular transcriptional activity through 
degradation or translation-arrest of the target mRNA in a sequence-specific manner16. The 
effector molecules of RNAi are small double stranded RNA (dsRNA) molecules of ≈22 nucleotides 
(nt). Two pathways exist; one wherein the effector RNA molecule may be of endogenous origin 
and the final effector RNA has 1-3 mismatches with the target sequence. In this pathway, the 
effector RNAs are called miRNAs. In the other pathway, which is the one relevant to this 
dissertation, the effector RNAs are called small interfering RNAs (siRNA), are of exogenous 
origin, and has complete complementarity with the target mRNA sequence18–20 (Fig. 1.1). siRNAs 
may be introduced into the cytosol in their final form of ≈22 nucleotide (nt) double stranded 
RNAs (dsRNAs) with a symmetric 2-nt overhang at the 3’-end of each strand21, or as larger 
dsRNAs. dsRNAs larger than ≈22 nt will be trimmed to the short ≈22 nt form upon entry into the 
cytosol by a ribonuclease III-type protein called Dicer22. After generation of the ≈22 nt duplexes, 
the siRNAs are incorporated into a protein complex called the RNA-induced silencing complex 
(RISC), where the siRNA is unwound and the sense strand (or passenger strand) is cleaved. The 
activated RISC, which now only contains the antisense strand (or guide strand) of the original 
siRNA duplex, selectively pairs with and degrades mRNA that is complementary to the antisense 
strand, and as each activated RISC complex can perform many targeted degradations, siRNA-
mediated RNAi is extremely potent23. This potency ensures a therapeutic effect for 3–7 days in 
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rapidly dividing cells, and for several weeks in non-dividing cells24. Eventually, the siRNAs are 
diluted below a certain critical threshold or degraded within the cell, and so – in a therapeutic 
setting – repeated administration is necessary to achieve a persistent effect. Theoretically, when 
using appropriately designed siRNA, the RNAi machinery can be exploited to silence nearly any 
gene in the body, giving it a much broader therapeutic potential than typical small-molecule 
drugs. As cancers are characterized by upregulated or inappropriately expressed genes that lead 
to uncontrolled cell growth, RNAi represents an attractive treatment strategy for many types of 
cancer. 
 
Figure 1.1. Cartoon of the mechanism of RNAi by siRNA in mammalian systems. Long double-stranded RNA molecules (dsRNA) enter 
the cell (arrow 1), are processed by the Dicer complex resulting in the formation of small interfering RNAs (siRNAs). Alternatively, 
siRNAs of ≈22 nt duplexes are delivered directly into the cell (arrow 2). The siRNAs are incorporated into the RNA-induced silencing 
complex (RISC), which becomes activated upon the ATP-dependent unwinding of the siRNA duplex. The passenger strand (blue) is 
cleaved and the now single-stranded siRNA guide strand (red) guides RISC to its complementary target mRNA. After base-pairing with 
the target mRNA sequence, the mRNA molecule is cleaved by the endonucleolytical activity of RISC. While RISC is recovered for 
further cycles, the cleaved targeted mRNA molecule is rapidly completely degraded due to its unprotected ends. Figure modified 
from25. 
1.4 Delivery of siRNA to the target cells 
While siRNA therapy takes advantage of cellular machinery located in the cytosol and avoids 
transport of the nucleic acid cargo into the nucleus, the many barriers between the cytosol of 
the cell and the point of administration remain a formidable challenge to systemically 
administered siRNA, and the delivery obstacles have turned out to be rate-limiting in the 
development of RNAi-based therapies23. To overcome the challenges posed by the many 
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barriers, a delivery vehicle (termed a vector) is employed, and the field is separated according to 
the type of vector; whether it is a lipid or polymer (non-viral delivery), or a genetically modified 
virus (viral delivery). The pros and cons of both types of delivery are briefly discussed in section 
1.5 and an overview of the barriers to non-viral siRNA delivery is provided immediately below. 
1.4.1 Stability in the circulation 
Upon entry into the blood stream, the stability of the siRNA and vector-siRNA complex is 
challenged by a variety of blood components. The most important and abundant threat comes 
from ribonucleases, which are present ubiquitously as part of the defense against retroviruses, 
and degrade unprotected nucleic acids with high efficiency26. Accordingly, the siRNA needs 
protection against nucleolytic attack. 
Electrostatic interaction with blood components is another obstacle to successful non-viral 
delivery of siRNA. Particles with a net cationic charge will interact with negatively charged blood 
components, such as serum proteins, which may lead to recognition by phagocytes and fast 
clearance from the circulation26. Particles with an overall charge, positive or negative, may 
aggregate in the bloodstream due to the presence of ions in the blood, which can shield the 
electrostatic repulsion between charged particles (a phenomenon known as salt-induced 
aggregation). Aggregation may increase phagocytic clearance as well as cause blocking of 
microvessels27. Conversely, particles with a diameter below 5 nm will be cleared rapidly by the 
glomerular filtration28 highlighting that size and surface charge are very important properties for 
successful siRNA delivery. 
1.4.2 Egress from the bloodstream  
To exit the blood stream and accumulate in the target tissue, the siRNA-particles need to cross 
the vessel endothelium. While most capillary endothelia are impermeable to large molecules, 
vessels in inflamed and tumorous tissue have been shown to be “leaky” due to inflammation, 
rapid growth and/or angiogenesis. Combined with the lack of lymphatic drainage in tumor 
tissues, this permeability facilitates non-specific egress of macromolecules from the bloodstream 
into the tissue6,28. The phenomenon is known as the enhanced permeation and retention effect 
(EPR effect), and has been used to explain the increased accumulation of nanosized particles in 
tumorous tissues compared to other tissues. However, the EPR effect has also shown to be 
highly variable between different types of cancer and tissue, and evidence also suggests that the 
EPR effect is much more pronounced in mice and dogs than in humans29. In the absence of EPR-
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like conditions, accumulation of nanoparticles in the tissues requires passive trans- or 
paracellular transport or the exploitation of active transport mechanisms28. 
1.4.3 The extracellular matrix  
Following exit from the circulation, the transfection particles must diffuse through the 
extracellular matrix to the target cells in order for cellular uptake to occur. However, the 
extracellular matrix consists of a dense layer of polysaccharides and fibrous proteins and may 
slow down diffusion dramatically. A major component of the extracellular matrix is the 
proteoglycans, which consist of a core protein covalently linked to one or more anionic 
glycosaminoglycans (GAGs). The GAGs may interact with positively charged transfection 
particles, causing reduced mobility. They may also compete for binding to the vector, thus 
causing decondensation or release of the nucleic acid30.  Finally, the extracellular matrix is 
particularly rich in nucleases, underlining the importance of nucleolytic protection of the siRNA. 
Unsurprisingly, it has been shown that the cellular uptake decreases with the amount of 
extracellular matrix needing to be traversed31. 
1.4.4 Cellular entry  
To enter into the target cell, the transfection particles have to cross the plasma membrane. As 
passive diffusion across the plasma membrane is restricted to very small and hydrophobic 
entities6, entry into the cell must follow other routes. While a recent interesting report 
hypothesized that a very small fraction of siRNA-lipoplexes (transfection particles consisting of 
cationic lipids and siRNA) was taken up through some form of direct membrane fusion and was 
responsible for all of the observed knockdown32, most investigators currently believe that the 
internalization occurs through some form of endocytosis. Endocytosis is a cellular mechanism for 
uptake of macromolecules and solutes into membrane-bound vesicles derived by invagination 
and pinching off pieces of the plasma membrane33. Several different endocytic routes are known 
and the specific type of endocytosis employed for the uptake of a given transfection particle 
appear to depend on the biophysical characteristics of the particle, the cell in question and the 
possible presence of targeting ligands on the surface of the particles33. Some gene delivery 
vectors are believed to facilitate endocytosis unspecifically. For instance, it appears that 
endocytosis can be triggered by non-specific electrostatic interactions between positively 
charged transfection particles and negatively charged glycoproteins and proteoglycans on the 
cell surface in a process termed adsorptive pinocytosis34. However, while several groups have 
attempted to elucidate which type of non-viral transfection particle is preferentially taken up by 
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a given subform of endocytosis, the picture remains diffuse. The matter is further complicated 
by disagreement on the types of endocytosis possible – several groups remain skeptical towards 
the existence of caveolar endocytosis, claiming microscopic artefacts and physiologically 
irrelevant experimental circumstances to be at fault35. 
Regardless of the route of endocytosis, it has been shown that the size of the particle strongly 
affects cellular uptake and the optimal particle size using non-targeting vectors is assumed to be 
between 70 and 100 nm26,29.  
Other approaches to improve cellular internalization than receptor targeting have been 
examined, including the application of physical stress to the tissue in question in order to 
transiently disrupt the plasma membrane. However, these methods are highly invasive, damage 
the cells and the treatment cannot be utilized in deeper tissues. The use of cell penetrating 
peptides is another approach that has received some attention, but this strategy has also been 
associated with substantial unintentional cell damage6. 
1.4.5 Endosomal escape and intracellular trafficking 
After internalization by endocytosis, the polyplexes are trapped in the endosomal compartment, 
specifically in the early endosome (Fig. 1.2). The early endosomes undergo a series of fusion 
processes during which some level of sorting of the internalized material takes place. Some of 
the internalized material, e.g. some internalized cell surface receptors, is recycled to the plasma 
membrane. Material which is not redirected to the plasma membrane remains in the endosome, 
which undergoes further vesicular fusions during which the internalized material reaches first 
the late endosomal compartment and finally the lysosomal compartment. During the course of 
this journey, the interior pH of the vesicle is gradually lowered because the V-ATPase pumps H+ 
into the vesicle under the consumption ATP, followed by the passive influx of Cl-26. The pH 
decrease culminates at pH 4.4 after fusion with the lysosomes, which also introduces a cocktail 
of acid hydrolases6,36. The acid hydrolases are enzymes capable of degrading most bio-polymers 
and lysosomal degradation is therefore a major bottleneck for efficient gene delivery. 
Consequently, for transfection particles taken up by endocytosis, it is crucial that the particles 
are able to escape from the endosomes before fusion with the lysosomes, a phenomenon 
referred to as “endosomal escape”. Viruses are able to escape from endosomes due to their 
contents of peptides with pH-triggered fusogenic activity, which can destabilize the endosomal 
vesicles37, but only a subset of non-viral vectors possess this ability. For polycations, this ability 
has been shown to correlate with their buffering capacity in the pH range 5-737.  
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Figure 1.2. Intracellular trafficking of an siRNA transfection particle. An siRNA transfection particle is taken up into the cell by 
endocytosis, with cellular association mediated by interaction with a negatively charged proteoglycan. The endocytic vesicle is 
pinched off and fuses with the early endosomal compartment. The contents of the early endosome are trafficked to the sorting 
endosomal compartment, where recycling of selected cargo takes place. Then follows fusion with the late endosomal compartment 
and finally the lysosomal compartment, which is the site of hydrolysis of proteins and nucleic acids. Throughout the journey, the pH 
of the endosomal interior is gradually lowered through the action the V-ATPase culminating at pH 4.4 in the lysosomes. To direct 
silencing of the target gene, siRNAs must escape from the endosome into the cytoplasm before fusion with the lysosomal 
compartment and introduction of the acid hydrolases to avoid degradation. Modified from25. 
Following escape from the endosomes, the siRNA has to reach the RNAi machinery intact and be 
loaded into the RISC. As the cytosol contains numerous nucleases, the protection afforded by 
the vector is again of great importance, especially since diffusion in the cytosol is slow38. Further, 
for loading of the siRNA into the RISC protein assembly to be possible, the siRNA needs to 
dissociate from the vector at just the right place, which means that there is a delicate balance 
between a vector-siRNA association that is of exactly the right strength, and associations that 
are too weak/unprotective or too strong. 
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1.5 Viral and Non-Viral vectors 
Some experimental treatments with DNA have achieved positive results using electroporation-
assisted delivery39 or “gene guns”40 to force naked nucleic acids into cells. However, due to the 
barriers described in the previous sections, systemic and efficient delivery of siRNA necessitates 
some form of delivery vehicle, which is termed a vector. 
Most clinical trials and experimental treatments use viral vectors41, which are attenuated 
viruses. Virus propagation rely on the manipulation of host cells to produce new viral proteins by 
introducing nucleic acids into the host protein machinery, and evolution has perfected 
parameters such as stability towards the environment, efficiency of transfection and methods to 
ensure high volume expression of the cargo. 
However, application of viral vectors has so far been restricted by a number of factors42–44: 
• high complexity of vector preparation which greatly increases the therapeutic costs 
• limited loading capacity of the viral vectors 
• safety concerns due to the oncogenic potential of viral delivery 
• risk of reversion to wild-type with restoration virulence due to the large amounts of 
ancient viral DNA material present in the human genome 
• inflammatory and immunogenic effects which prevent repeated administration 
In light of these concerns and challenges, synthetic vectors have been developed. They are oligo- 
or polycations of various types, which are able to form stable complexes with the negatively 
charged siRNA resulting in particles with varying biophysical properties (e.g. particle size and ξ-
potential), which are important in determining the delivery capability of the vector. Non-viral 
vectors are less immunogenic and show much better overall safety profiles than viral vectors. 
Unfortunately, this comes at the expense of efficiency and many non-viral vectors also show 
substantial cytotoxicity. Thus, much of the research into non-viral siRNA delivery has focused on 
improving these parameters. 
The major classes of non-viral vectors are cationic lipids and cationic polymers37 and before 
focusing on the cationic polymer PEI, both classes will be described in overview immediately 
below.  
1.5.1 Cationic polymers  
Cationic polymers are synthetic compounds, which are easily modified with respect to average 
Mw and attachment of ligands45. The complexes formed between nucleic acids and polymers are 
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known as polyplexes. While rarely used unmodified in clinical trials, polymers are frequently 
used experimentally both in vitro and in vivo. Polyethylenimine (PEI) and various forms of poly-L-
lysine (PLL, Fig. 1.3) are commonly used cationic polymers for gene delivery, but also polymers 
such as chitosans46 (linear aminopolysaccharides) and dendrimers45 such as highly branched 
polyamidoamines have been used. A detailed introduction to PEI is given in section 1.6. 
PLL was one of the first polycations used for gene delivery and is a biodegradable linear 
polypeptide, with lysine as the repeating unit26. Importantly and in contrast to PEI, PLL itself is 
unable to facilitate endosomal escape. At physiological pH, all the primary amine groups of PLL 
will be protonated and therefore the polymer has no significant buffering capacity. 
Consequently, transfection using PLL requires co-administration of a lysosomotropic agent, such 
as chloroquine, or a fusiogenic peptide, which can facilitate the crucial endosomal escape47. As 
for PEI, the Mw of PLL has great influence on PLL’s properties as gene delivery vector and in 
general PLL with Mw above 3 kDa is required for formation of stable transfection particles. The 
transfection efficiency increases with increasing Mw, but – unfortunately – so does 
cytotoxicity48. 
 
Figure 1.3. Structure of poly-L-lysine homo-polymer fragment (PLL). 
1.5.2 Cationic lipids  
Transfection using cationic lipids is often called lipofection and was described in as early as 
198749. The cationic lipids used for lipofection all contain a hydrophilic cationic head group and 
fatty acid side chains26. Owing to their amphiphilic properties, the lipids may self-assemble in 
aqueous environments. When mixed with siRNA, a variety of structures may be formed, the 
most common of which appear to be siRNA sandwiched between the layers of multilamellar 
vesicles (lamellar phase) or siRNA inserted within inverse lipid tubules, arranged on a hexagonal 
lattice (inverted hexagonal phase)50.  
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A number of commercially available lipofection reagents exist (Fig. 1.4) and clinical studies have 
also been performed using cationic lipids, but so far no systems have reached the clinic due to 
cytotoxic effects and insufficient transfection efficiency41. Rapid clearance of particles which 
carry a net cationic charge is a major reason for the low efficiency, and accordingly several 
strategies have been devised to produce transfection particles which carry a neutral charge in 
the circulation. One strategy has been to use titratable cationic lipids enabling the charge of the 
formulated transfection particles to be adjusted to neutral at physiological pH after complex 
formation51. As positive charges facilitate cellular internalization, another promising strategy has 
been shielding the positive charges when the transfection particle is in the circulation followed 
by de-shielding in the target tissue through the action of tissue-specific proteases52. 
 
Figure 1.4. Structures of some commercially available lipofection reagents26. A. DOTMA, (Lipofectin®, 2-di-O-octadecenyl-3-
trimethylammonium-propane), B. DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), C. DOGS (Transfectam®, 
Dioctadecylamidoglycyl-spermine), D. DOSPA (Lipofectamine®, 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-
propanaminium-trifluoroacetate).  
1.6 Polyethyleneimine (PEI) 
PEI is a synthetic polymer, which has been widely used for various industrial applications for 
more than 40 years. PEI exists in linear and branched forms (abbreviated lPEI and bPEI, 
respectively, Fig. 1.5), each covering a wide range of average molecular weights, ranging from 
100 Da to 1500 kDa53,54. As every third atom is an N, potentially capable of protonation, PEI has a 
very high charge density potential55. Importantly, the charge density is highly pH-dependent: At 
physiological pH (pH 7.4), only ≈20% of the nitrogens are protonated, while a decrease to pH 5 
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increases this percentage to ≈4556. Combined, the many proton-accepting groups and the wide 
range of apparent pKa values provide PEI with high buffering capacity over a wide pH range53,57, 
which has been used to explain the efficiency of PEI as a transfection agent. lPEI and bPEI differ 
in the nature of their amines with lPEI containing almost exclusively secondary amines and bPEI 
containing a mixture of primary, secondary and tertiary amines. The ratio of the different amines 
on bPEI depends on the details of the synthesis, with most commercially available bPEI polymers 
having a ratio of primary to secondary to tertiary amines of 1:1:156. PEI polymers have maximum 
buffer capacity between pH 8-10, and at a given pH in this range bPEI will show a higher charge 
density than lPEI, but at the endosomal pH range (pH 4-6), no effect of polymer structure on 
protonation has been demonstrated53,58. 
 
Figure 1.5. Structures of A. a typical linear PEI fragment (lPEI) and B. a typical branched PEI fragment (bPEI). 
PEI forms the basis for a number of commercially available transfection agents for non-clinical 
use, and remains the “gold standard” for non-viral gene delivery vectors. However, while PEI is a 
potent transfection agent, the delivery efficiency of PEI-based transfections agents is still unable 
to compete with viral vectors54,59. 
1.6.1 How does PEI facilitate transfection? 
Due to the high charge density, PEI is excellent at condensing the siRNA into small, compact 
transfection particles with an overall positive charge and protecting the siRNA against 
degradation by nucleases. Excess cationic charges have the ability to interact non-specifically 
with negatively charged glycoproteins and proteoglycans on the cell surface and may thus 
facilitate the uptake process54,60. Some reports claim to demonstrate internalization specifically 
though caveolar endocytosis54, which should be beneficial as this pathway may avoid fusion with 
the lysosomes33. Regardless of internalization route, PEI is hypothesized to be able to facilitate 
endosomal escape although the mechanism for this is not fully understood. The dominant 
hypothesis is termed the “proton sponge effect” and states that PEI, through the many 
unprotonated amines left over from polyplex formation with the cargo, is able to absorb protons 
when the complex travels through the gradually more acidic endolysomal compartments. This 
will then lead to excessive H+ influx as the V-ATPase attempts to compensate for the H+ 
N
N
H
N
N
H
N
NH2 N
H
NH2
N
H2N NH2 n
n
N
H
H
N
A B
 
 
15 
 
Project I  
 
absorption of PEI, leading to increased co-influx of Cl- and water61, which in turn leads to osmotic 
swelling, destabilization and/or rupture of the lysosomal membrane and release of the siRNA 
into the cytosol62. However, the proton sponge effect is debated and incontrovertible 
experimental evidence remains elusive. As theoretical assessments have indicated that 
internalization of realistic amounts of bPEI-polyplexes is insufficient to cause rupture of the 
endosomal membrane, it has been hypothesized that the proton sponge effect is only a 
contributor to endosomal escape, possibly through local destabilization of the endosomal 
membrane63. The latter is viewed as congruent with observations of pore formation in the 
endosomal membrane after treatment with PEI64. As the endosomal escape properties of PEI 
by some has been viewed as the most important factor limiting PEI mediated transfection, 
several attempts have been made to enhance this property e.g. using membrane-destabilizing 
proteins or peptides25. However, these attempts have not been successful, which have led some 
to conclude that the inherent endosomal escape properties of PEI itself are not the bottleneck to 
the overall performance of PEI54.  
It remains unclear, exactly when de-complexation of the polyplexes takes place once endosomal 
escape has occurred, and how siRNA in condensed or de-condensed form is loaded into the RNAi 
machinery. While post-endosomal escape activities are not regarded as rate-limiting in the 
delivery process65, it is intuitive that a balance between tight binding of the cargo and facile 
release exists. 
The physical, chemical and biological properties of PEI has been found to depend highly on its 
structure59,66. A wide variety of PEI polymers have been tested, but no structure has been found 
unequivocally superior54 and the structure-activity relationship is still not fully understood - 
including whether lPEI or bPEI provides the best results60. As seen for PLL, the transfection 
efficiency of PEI increases with MW, but so does cytotoxicity and an average MW of 25kDa is 
generally considered the upper limit for usability of PEI for transfection. 
1.6.2 Structure of PEI polyplexes 
PEI polyplexes have not been characterized to the same detail as lipopolexes in terms of 
structure, with most studies using PEI focusing on the fate of the complexed siRNA. As 
mentioned, it has been shown that PEI is able to condense siRNA into transfection capable 
particles in which the siRNA is protected against degradation by nucleases. In addition, 
experiments on bPEI and sRNA67 indicate that in the presence of a long-chain polycations (bPEI 
25kDa), the polyanion is neutralized and totally surrounded by the oppositely charged chains, 
 
 
16 
 
Background 
 
while with the shorter polycation chains (bPEI 2.7kDa), the siRNA is condensed but more 
exposed to the outside. In both cases the formed particles were spherical67. 
1.6.3 Modifications of PEI 
Since the emergence of PEI as an efficient transfection agent, many diverse strategies have been 
employed attempting to reduce the toxicity while retaining the delivery efficiency: PEGylation 
(conjugation to poly(ethyleneglycol)) with or without addition of a targeting moiety53, cross-
linking of bPEI 2kDa and lPEI 423Da via ester- and/or amide- linkages68, acylation with oleic 
acid69, acylation and crosslinking using PEG as crosslinker70 and lipid conjugation71–73. Lipid 
conjugation is a highly promising strategy as lipid-lipid interactions are orthogonal to the 
interaction sequestering the siRNA in the polyplex and thus may be exploited and manipulated 
separately. In addition, possible cell entry / endosomal escape mechanisms may work 
independently of the siRNA condensation, which could be an advantage. Finally, while lipid-
conjugated cations cannot be assumed to behave similarly to cationic lipids due to the different 
ratio between charged and lipid moieties, a lot of information regarding the structure of 
lipoplexes and siRNA exist50,74–77, and this may prove a useful starting point for the rational 
development of future lipid-conjugated PEI-based vectors for siRNA delivery. 
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2 Aim of Project I 
The aim of Project I was to investigate mechanistic and biological aspects of siRNA delivery using 
bPEI and one of the most promising types of PEI modification, namely a lipid conjugate of bPEI. 
Project I focused on the vector-to-cargo ratio and examined whether a free vector fraction exists 
when bPEI and bPEI-lipid conjugates are used for siRNA delivery. Further, Project I investigated 
the impact of the free fraction on the ability of bPEI and the bPEI-conjugate to facilitate siRNA 
internalization and knockdown of reporter gene expression as well as the importance of the free 
fraction for the cytotoxicity of the vectors and polyplexes. Finally, Project I examined the 
potential effect on pH in the lysosomes induced by these polycations to elucidate the differences 
in the proton sponge effect between lipid-conjugated PEI and conventional PEI. 
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3 Article 1: Elucidating the role of free polycations in gene 
knockdown by siRNA polyplexes 
This section contains the manuscript prepared for submission to Biomaterials. 
 
Thomas C. B. Klauber1, Rikke V. Søndergaard1, Rupa R. Sawant2, Vladimir P. Torchilin2, Thomas L. 
Andresen1 
1DTU Nanotech, Department of Micro-and Nanotechnology, Center for Nanomedicine and Theranostics, Technical 
University of Denmark, Building 423, 2800 Lyngby, Denmark 
2Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA  
 
 
3.1 Abstract 
Future improvements of non-viral vectors for siRNA delivery require new mechanistic 
understanding of intracellular processing and vector interactions with target cells. In the present 
work, we have compared the siRNA delivery properties of a lipid derivative of bPEI 1.8kDa 
(DOPE-PEI) with branched polyethyleneimine (bPEI) with average molecular weights of 1.8kDa 
(bPEI 1.8kDa) and 25 kDa (bPEI 25kDa). We have investigated the potential effect on pH in 
lysosomes induced by these synthetic vectors in order to elucidate the differences in the proton 
sponge effect between lipid conjugated PEI and conventional PEI. We find mechanistic 
differences between the DOPE-PEI conjugate and bPEI with respect to siRNA condensation and 
intracellular processing. bPEI 1.8kDa and bPEI 25kDa have similar properties with respect to 
condensation capability, but are very different with respect to siRNA decondensation, cellular 
internalization and induction of reporter gene knockdown. Lipid conjugation of bPEI 1.8kDa 
improves the siRNA delivery properties, but with markedly different formulation requirements 
and mechanisms of action compared to conventional PEIs. Furthermore, cellular incubation with 
either DOPE-PEI or bPEI 25kDa did not affect lysosomal pH as a function of time, underlining that 
the possible proton sponge effect is not associated with changes in pH. 
Keywords: siRNA, Polyethyleneimine, PEI, Non-viral gene delivery, Proton sponge effect, 
Polycation 
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3.2 Introduction 
RNA interference (RNAi) based drugs are currently under intense investigation for treating viral 
infections, cancer and neurological disorders78.  RNAi is a naturally occurring post-transcriptional 
gene-silencing mechanism for regulating cellular transcriptional activity through degradation or 
translation-arrest of the target mRNA65. The most extensively described form of RNAi acts 
through small interfering RNAs (siRNAs), which have complete sequence complementarity with 
the target mRNA. The siRNAs can be transfected into cells in their short active form or generated 
intracellularly from longer double stranded RNAs (dsRNAs)22,79.  
The safe and efficient delivery of siRNA specifically to target cells is essential to RNAi-based 
therapy, but remains a major challenge80. Many attempts have relied on modified viruses, which 
- while very efficient - are challenged by the possibilities of insertional mutagenesis, immune 
responses or severe systemic toxicity as well as scalability issues and the possibility of reversion 
to transmissible forms8. As a consequence, non-viral vectors, which are characterized by low 
host immunogenicity and easy manufacturability, have attracted considerable attention and 
successful development of a safe and efficient non-viral delivery system would be one of the 
most important achievements in medicine today26,81.  
Cationic polymers are attractive for delivery of siRNA (and DNA) since they are particularly easy 
to formulate with poly-anionic nucleic acids. The electrostatic interactions between the anionic 
phosphates in siRNA and the cationic moieties in the polymers can assemble the siRNA into 
nanoparticles - polyplexes - suitable for cellular uptake. Vectors based on polyethylenimine (PEI) 
were among the first to emerge and are still considered the gold standard in polymer based DNA 
delivery53–55,60 and have also turned out to be efficient siRNA delivery agents in vitro82–84.  
In spite of the huge activity in the field and the broad use of cationic polymers as siRNA delivery 
agents, several aspects about their mode of action remain unclear. Polyplexes are generally 
believed to enter the cell via endocytosis, thus a primary research focus has been to ensure 
endosomal escape to avoid degradation in the lysosomes85,86 and achieve release of the cargo 
into the cytosol. One of the key advantages of cationic polymers is their alleged ability to 
facilitate the so-called proton sponge effect55, which is believed to be associated with 
endosomal/lysosomal escape of the polyplexes or their components. In PEI, the many 
protonated amines facilitate strong binding to siRNA to form polyplexes, while the unprotonated 
amines of PEI are able to absorb protons when the complex enters acidic compartments 
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(endosomes and lysosomes). The proton sponge effect is believed to result in excessive V-
ATPase mediated H+ influx, which leads to increased influx of Cl- and water, and in turn this may 
lead to osmotic swelling, destabilization and/or rupture of the lysosomal membrane and release 
of the siRNA into the cytosol62. However, the proton sponge effect is debated and 
incontrovertible experimental evidence remains elusive. An alternative hypothesis is that 
polyplexes are internalized via the caveolar pathway that bypasses the endolysosomal pathway 
altogether87, but the existence of a physiologically relevant caveolar pathway with a role in 
constitutive endocytic trafficking is equally debated35,88,89.  
One limitation of PEI as a transfection agent has been the necessity to use PEIs of high average 
molecular weight (Mw) to achieve efficient transfection. Unfortunately, there is a direct 
correlation between the Mw and the toxicity of PEI90. Several approaches to circumvent this 
have been explored, one of the more promising being to use low-Mw PEI with low toxicity, e.g. 
PEI 2kDa91, and improve the otherwise poor transfection efficiency of such PEIs by incorporating 
hydrophobic moieties onto the polymer amines. The hydrophobic substituents are expected to 
increase the ability of the PEIs to form polyplexes and increase the interaction of the polymer 
with the cell membrane. Such a beneficial effect of lipid substitution has been established in the 
context of plasmid DNA delivery for several cationic carriers72,92 and more recently for delivery of 
siRNA71,91,93,94.  
An important aspect of polycation based gene delivery is the polymer/siRNA ratio necessary to 
obtain high transfection efficiency. This issue has been addressed thoroughly for PEI mediated 
DNA transfection95–97, where it was found that a free (non-condensed) fraction of PEI is very 
important for achieving high transfection levels. However, as size, electrostatic charge and 
intracellular compartment of action differ for siRNA compared to DNA, it is not clear how a free 
fraction of PEI influences gene silencing. For in vivo use, a potential requirement for a free 
fraction for achieving high gene silencing efficiency is a major obstacle for the use of PEI and 
other polycations for non-viral gene delivery. Such systems are challenged by the fact that highly 
cationic entities will interact strongly with anionic blood constituents, the immune system and 
cells in general, and will therefore not allow for targeting of diseased tissue. In order to 
rationally develop efficacious siRNA carriers, it is essential that the interplay between the above-
mentioned properties is understood.  
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In the present study we compare lipid derivatized PEI in the form of a dioleoylphosphatidyl-
ethanolamine (DOPE)-bPEI 1.8kDa conjugate (DOPE-PEI) with conventional bPEI 1.8 kDa and bPEI 
25kDa to establish to what extent the lipid conjugation alters the condensation properties of 
siRNA, cellular delivery and silencing of a reporter gene as well as to what extent the toxicity of 
the transfection agent is reduced. We further investigate and compare how PEI and lipid 
conjugated PEI affects the pH in the lysosomes, as an increase in lysosomal pH has been 
associated with the proton sponge effect. Lastly, we have systematically investigated the impact 
of lipid conjugation to bPEI in relation to the use of excess transfection agent beyond the 
requirement for full condensation of the siRNA (termed the “free fraction”) and the silencing 
efficiency in comparison to bPEI itself. 
 
3.3 Materials and Methods 
3.3.1 Materials and Cell Lines 
Branched PEI with a weight-averaged molar mass of 25,000 g/mol (bPEI 25kDa) and 1,800 g/mol 
(bPEI 1.8kDa) were purchased from Sigma-Aldrich (US) and used without further purification. 
Before use they were dissolved in MQ water to a concentration of 15.4 mM with respect to 
nitrogen and further diluted in Hepes buffed glucose (HBG: 10 mM Hepes, 5% w/v glucose, pH 
7.4) as needed. DOPE-PEI was synthesized as described by Sawant et al.72 and kindly supplied by 
Professor Vladimir Torchilin’s laboratory as a lyophilized powder and dissolved in MQ water to a 
concentration 1 mg/mL and further diluted in HBG as needed. All siRNA duplexes were 
purchased from Eurofins MWG Operon (Germany): siRNA targeting green fluorescent protein 
(GFP-siRNA): 5′-GGCUACGUCCAGGAGCGCACC(dTdT)-3′ (sense) and siRNA targeting Luciferase 
(5′-CUUACGCUGAGUACUUCGA(dTdT)-3′ (sense). PicoGreen and Lipofectamine® RNAimax were 
purchased from Invitrogen (US) and Na-Heparin from porcine intestinal mucosa was purchased 
from Sigma-Aldrich (US). The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
(MTS) was purchased from Promega (US).  
The cell line HT1080 (human fibrosarcoma, ATCC no. CCL-121) was transfected to stably express 
luciferase and is referred to as HT1080pLUC. The cells were cultured at 37°C, 5% CO2 in RPMI 
1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, heat-inactivated, Fisher 
Scientific), penicillin at 100 units/mL (pen), streptomycin at 100 mg/mL (strep), and Genticin 
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(G418) at 0.8 mg/mL (all from Sigma-Aldrich). For knockdown experiments the selection 
antibiotic, G418, was omitted from the culture medium. 
3.3.2 Methods 
Preparation of polyplexes 
The N/P ratio of the present polyplexes is defined as the molar ratio of the total number of 
nitrogen atoms in the PEI segment of the polymer or lipid-cojugated polymer to the number of 
siRNA phosphates. Polyplexes with varying N/P ratios were formulated by adding a volume (≈35 
µL) from an siRNA solution in water to an equal volume of a solution of cationic polymer diluted 
in HBG. The final siRNA concentration was kept constant while the bPEI concentration was 
varied with the different N/P ratios. Each resulting formulation mixture was first mixed by 
pipetting up and down 10 times, then vortexed gently for 15 s and then incubated for 45 min at 
RT before further use. The final concentration of siRNA in all formulation mixtures was 0.039 
µg/µL. 
Size and ξ-potential of polyplexes  
The hydrodynamic diameter (particle size), polydispersity and ξ-potential of the polyplexes were 
determined using dynamic light scattering (DLS) on a ZetaPals (Brookhaven Instrument 
Corporation, Holtsville, NY, USA) at 25°C with an angle of 90°. Before ξ-potential measurements 
the electrode was conditioned in a 1 M KCl solution. Polyplexes were prepared as described 
above and diluted up to a volume of 1.75 mL in HBG and measured immediately after 
preparation. The particle size was determined by five runs of 30 s each on three separate 
preparations. ξ-potential determination of each sample was carried out by 10 runs with a target 
residual of 3.5 x 10-2, three separate preparations per N/P ratio. 
PicoGreen exclusion assay and heparin competition assay 
The complex formation between siRNA and the cationic polymers was studied in an exclusion 
assay using the fluorescent intercalating dye PicoGreen. PicoGreen shows maximum 
fluorescence at 535 nm when it intercalates between the bases in double stranded RNA (and 
DNA) while showing virtually none in the absence of intercalation, and is thus a highly sensitive 
detector of accessible siRNA, in this case meaning uncomplexed siRNA. Polyplexes were 
prepared at different N/P ratios at RT as described above and transferred to a dark microtiter 
plate and PicoGreen solution was added. The fluorescence of the polyplex dispersions was 
measured 10 min after addition of PicoGreen. A Victor 3 plate reader (Perkin-Elmer, US) was 
used to measure the fluorescence (λex = 485 nm, λem = 535 nm). 
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To study the dissociation of the polyplexes when exposed to a competing polyanion, increasing 
amount of heparin was added to the polyplex dispersions after 45 min incubation. When the 
negatively charged heparin is added to the dispersions of the polyplexes, it competes with the 
siRNA for binding to the cationic bPEI, potentially leading to the displacement of siRNA from the 
polyplex. The resulting mixtures were incubated for 30 min at RT and measured on the Victor 3 
plate reader. The relative fluorescence values and thus the percentage of accessible (= 
uncondensed) siRNA were determined and reported as percent fluorescence of free siRNA in the 
absence of vector. All results are corrected for fluorescence quenching by heparin and each 
experimental condition was done in triplicates. 
Gel electrophoresis visualization of the siRNA condensation 
The polyplex formation between siRNA and the polycations was further evaluated using agarose 
gel electrophoresis; exploiting the fact that naked siRNA readily migrates in an agarose gel while 
polyplexes are retained in the wells. Each preparation of polyplex with a desired N/P ratio was 
loaded onto a 2% (w/v) agarose gel containing ethidium bromide (Sigma-Aldrich) in Tris-Acetate 
EDTA buffer. The amount of siRNA loaded into each well was 69 pmol in a total volume of 12 μL 
including loading buffer (1 mM cresol red in 0.6 M sucrose). The electrophoresis was performed 
at 50 V for 35 min and siRNA bands were visualized using a BioSpectrum® Imaging System 
(excitation at 480 nm, emission filter at 570-640 nm.) 
Knockdown of luciferase expression 
HT1080 pLuc cells, which stably expressed luciferase, were seeded in RPMI 1640 medium with 
10% FBS, 5% pen/strep (complete medium) in 24-well plates 24 h prior to transfection (50,000 
cells per well). The cells were washed with PBS, polyplexes formulated as described above were 
further diluted in RPMI 1640 medium with 5% pen/strep (serum free medium) and added to the 
cells resulting in a final concentration of 120 nM siRNA per well. The cells were incubated with 
polyplexes for 6 h, transfection medium was removed, and the cells were washed with PBS and 
incubated for an additional 22 h in complete medium. The cells were then washed once with PBS 
and lysed using 125 µL Reporter Lysis Buffer (Promega, US). Luciferase activity was measured 
using a luciferase assay98 with D-luciferin (Caliper Life Sciences, US). Each sample was measured 
for 10 s on a luminometer (Lumat LB9507, Berthold, Germany). The total lysate protein 
concentration was determined using the BCA kit (Pierce, US) and the gene expression was 
normalized to the total protein concentration in the cell lysate and described as luciferase 
activity (relative light units) per µg protein. All knockdown assays comprised, as a positive 
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control, Lipofectamine® RNAimax using 30 pmol of siRNA. In addition, all assays comprised a 
non-sense control using siRNA directed against GFP as well as anti-luciferase siRNA 
administrated unassociated to vector. The non-sense control was prepared using N/P16 for 
DOPE-PEI and N/P3 for bPEI 25kDa and PEI 1.8kDa. Each experimental condition was done in 
triplicates. 
In order to examine the importance of the free fraction, the extra vector material was diluted in 
serum free medium and added to cell cultures which had already been incubated for 2 h with 
polyplexes formulated for full condensation of the siRNA. Specifically, HT1080pLuc cells were 
incubated with polyplexes formed at the N/P ratio of full condensation for 2 h (N/P2 for bPEI 
25kDa and N/5 for DOPE-PEI). Then, the free fraction was added to the incubations, resulting in 
a total N/P ratio of 3 for bPEI 25kDa and 16 for DOPE-PEI. The cultures were then incubated with 
the mix of fully condensed polyplexes and separately added free fraction for 1, 2, or 4 h resulting 
in a total incubation time of 3, 4 or 6 h. After end of incubation with the mix of polyplexes and 
separately added free fraction, the cells were washed in PBS, fresh complete medium was added 
and the cells were incubated to a total of 28 h until lysis and analysis of knockdown. Control cells 
were incubated in parallel with fully condensed polyplexes or optimally formulated polyplexes. 
Each experimental condition was done in triplicates. 
Radiolabeling of siRNA 
Luc siRNA (MWG Eurofins Operon, Germany) was labeled with radioactive 33P using the kit for 
phosphorylation of DNA with T4 Polynucleotide Kinase (Fisher Scientific, US). The T4 
Polynucleotide Kinase was used to catalyze the transfer of 33P from [γ-33P]-ATP (Perkin Elmer, US) 
to the free hydroxyl end (5’) of luciferase siRNA. The reaction was stopped by addition of EDTA 
and the product was purified using the QIAquick nucleotide removal kit (Qiagen, Germany). Care 
was taken not to damage any secondary structure of the siRNA, accordingly the reaction mixture 
was never heated above 40°C. 
In vitro cellular uptake 
For experiments with parallel determination of uptake and knockdown, the siRNA was spiked 
with 33P labeled siRNA. Knockdown assays were performed as described above and the 
experiments were terminated by removal of the medium, and the cells were washed with PBS 
containing 0.11 mg/mL heparin in order to remove polyplexes bound to the plasma membranes 
and once with PBS. The cells were then lysed as described above, luciferase and BCA assays were 
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performed, 65 µL lysate per population was mixed with 5 mL scintillation liquid (UltimaGold, 
Perkin Elmer, US), and radioactivity was measured as counts per minute using a scintillation 
counter (Beckman Coulter, US). Each experimental condition was done in triplicates. 
Cytotoxicity assay of polymers and polyplexes  
The cytotoxicity of free vector polymers and the corresponding polyplex dispersions was 
evaluated on HT1080 pLuc cells using the MTS assay (CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation assay, Promega, USA). Cells were seeded in a 96-well plate at an initial density 
of 10,000 cells per well in complete medium. After 24 h, free vector polymers or polyplexes were 
added to the cells at varying concentrations in serum free medium. The cells were incubated at 
37°C, 5% CO2 for 24 h. The MTS working solution was then added to each well (20 µL). The cells 
were further incubated for 1 h at 37°C and absorbance was measured (490 nm, Victor 3 plate 
reader). Cytotoxicity was reported as percent cell viability using untreated cells as 100% 
(triplicate measurements). 
Ratiometric pH measurements in the endolysosomal compartment 
Measurements of endolysosomal pH was performed largely as described in57,99. Briefly, HT1080 
cells were plated in Ibidi 8-well µ-slides (27,000 cells/well in 300 µL/well) in complete medium 
and incubated over-night. On day 2, medium was changed to complete medium with 25 µg/mL 
nanosensor. On day 3, cells were carefully washed once in PBS-Heparin (0.111 µg/mL heparin in 
PBS) and once in PBS in order to remove un-internalized nanosensor. Then vector polymers were 
added in the following concentrations: 0.73 μg/mL (bPEI 1.8kDa, bPEI 25kDa) and 5.7 µg/mL 
(DOPE-PEI) in imaging medium (full growth medium without phenol red). These concentrations 
are 10% higher than for any in vitro cell assay with polyplexes, but below a level where 
significant cytotoxicity is observed. Confocal images were recorded at 0, 2 and 6 h, where after 
the cells were washed once in PBS-Heparin and once in PBS. Additional images were then 
acquired 10 and 24 h after addition of bPEI. Images were captured by a Leica TCS SP5 confocal 
microscope with a 63x water-immersion objective. The microscope is equipped with an 
incubator box and CO2 supply for optimal growth conditions during imaging. Images were 
acquired with fixed settings for all samples and the corresponding calibration curve. Two-color 
images were obtained by sequential line scanning with the following excitation/emission 
wavelengths: 488/493-560 nm and 561/566-680 nm. At each time point, before imaging the PEI 
treated cells, a control experiment was performed in order to optimize the microscope settings. 
One well containing cells unexposed to bPEI or PEI-derivative, but with nanosensor, was treated 
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with 200 nM Bafilomycin A1 for 40 min and used to optimize microscope settings. This treatment 
increases the pH of the lysosomes and adjusting the imaging settings to achieve maximum signal 
for this sample, ensures optimal use of the dynamic range of the nanosensor. Ten images were 
acquired of this sample and of an untreated sample (no PEIs or Bafilomycon A1, but with 
nanosensor) where after 15 images were acquired of each of the three PEI samples (per time-
point). A calibration curve was prepared by diluting the nanosensor in buffers (20 mM 
phosphate/20 mM citrate/20 mM malate/100 mM NaCl) from pH 2.8-7.5 with a final nanosensor 
concentration of 10 mg/mL. Each solution (2.5 µL) was transferred to a diagnostic microscope 
slide, sealed with a cover glass and imaged. Image analysis was performed as described 
previously using a pixel based method99. Briefly, image processing was used in order to 
determine which pixels are actual signal from the nanosensor and the included pixels were then 
converted to pH via the calibration curve. pH histograms are presented as mean ± SEM. pH 
images were generated by coloring single pixels according to a linear pH color scale. Additionally, 
phase contrast images were acquired at 2, 6, 10 and 24 h time-points to confirm cell viability and 
illustrate non-toxic footprint of nanosensor. 
 
3.4 Results 
3.4.1 Cytotoxicity of vector polymers and polyplexes 
To establish the toxicity profiles of bPEI 25kDa, bPEI 1.8kDa and DOPE-PEI, we used a cell 
viability assay (Promega’s MTS kit) to investigate the free vector polymers (Fig. 3.1) and the 
siRNA containing polyplexes (Fig. 3.2). 
Figure 3.1 shows that all three polymers are associated with some cytotoxicity with bPEI 25kDa 
being the most cytotoxic. Importantly, formulation of the vectors into polyplexes greatly 
diminishes this inherent cytotoxicity, most pronounced for bPEI 25kDa and DOPE-PEI (Fig. 3.2). 
The selected N/P ratios are those involved in subsequent in vitro knockdown studies as 
described later in detail. 
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Figure 3.1. Cytotoxicity of vector polymers. The cells were treated with increasing concentrations of polymer for 24 h in serum-free 
medium before analysis by MTS assay. Results are presented as mean of triplicates ± SD. Trend lines are 5 parameter fits. Results are 
presented as mean of triplicates ± SD. Trend lines are 5 parameter fits. The figure is representative of three independent 
experiments. 
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Figure 3.2. Cytotoxicity of polyplexes. A. bPEI 25kDa, B. DOPE-PEI, C. bPEI 1.8kDa. The cells were treated with increasing 
concentrations of polymer for 24 h in serum-free medium before analysis by MTS assay. For reference, the total vector concentration 
in our in vitro assays at N/P3 is 0.667 μg/mL (bPEI 25kDa, bPEI 1.8kDa) and 5.2 μg/mL at N/P16 (DOPE-PEI). Results are presented as 
mean of triplicates ± SD. Trend lines are 4 parameter fits. Representative of three independent experiments each. 
3.4.2 Lysosomal pH 
The proton-sponge effect remains the dominant hypothesis used to explain the ability of PEI to 
promote high transfection levels. We therefore measured the lysosomal pH in cells incubated 
with PEI 1.8kDa, DOPE-PEI, and bPEI 25kDa using a ratiometric nanosensor57,99 to compare the 
lipid conjugated PEI with conventional PEIs. 
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Figure 3.3A shows that the pH distributions of the samples treated with bPEI 25kDa or DOPE-PEI 
do not differ from the untreated control cells, whereas the Bafilomycin A1 treated sample 
displays a significant increase in pH, confirming that the nanosensor is capable of measuring an 
increase in pH. The lysosomal pH is visually presented in Figure 3.3B which shows images from 
the 6 h time-point. A lack of change in color between the Control and DOPE-PEI treated cells 
indicates no change in pH. Finally, the pH as a function of time is presented in Figure 3.3C for the 
Control and DOPE-PEI treated samples under exactly the same conditions over a period of 24 h, 
and no change in pH is observed over time. Thus, we do not find that lipid conjugated PEI 
changes the pH in the endolysosomal compartment, which is thereby similar to our previous 
study evaluating the proton sponge effect of conventional PEI57. 
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Figure 3.3. Lysosomal pH in response to bPEI 1.8kDa, bPEI 25kDa, DOPE-PEI or Bafilomycin A1. HT1080pLUC cells with internalized 
nanosensor for 16 h were treated with bPEI 1.8kDa, bPEI 25kDa or DOPE-PEI for 6 h and imaged at the indicated time points. A. 
Histograms showing pH distributions of nanosensor containing cells without further treatment (Control) or treated with bPEI 25kDa, 
bPEI 1.8kDa, DOPE-PEI or Bafilomycin A1 (Baf). Bafilomycin A1 was always added 40 min prior to measurement. Data points are 
mean values ± SEM. B. Representative images of cells obtained after 6 h of incubation. Top row: bright field images. Bottom row: pH 
images. The ratio of the original pH-sensitive and reference signals was converted to pH via a calibration curve and images color 
coded according to the linear pH scale. No difference is observed between the control cells and the DOPE-PEI treated cells, whereas 
a clear change in color from yellow/green to cyan can be observed between the control cells and the Bafilomycin A1 treated cells. C. 
Measurements of lysosomal pH in response to DOPE-PEI over time compared to untreated control cells. Presented is mean ± SD of 
the pH frequency distributions obtained in A. Time-point zero was collected just before addition of vector. Representative of three 
independent experiments. 
Phase contrast images (Supplementary Fig. 3.1) indicate that the combined exposure to 
nanosensor and bPEI / bPEI-derivative has a minimal impact on cell viability at the 
concentrations used. Furthermore, we have previously established that the nanosensor does not 
affect cell viability57,99. 
3.4.3 Size and ξ-potential of the polyplexes 
Size and charge of polyplexes greatly influence the efficiency of cellular uptake. Therefore, the 
complex formation of bPEI 1.8kDa, bPEI 25kDa and DOPE-PEI with siRNA was characterized. In 
HBG, all three vectors are able to condense the siRNA cargo into small particles with DOPE-PEI 
consistently forming the smallest particles (Fig. 3.4A). The ξ-potentials of the polyplexes are 
positive at N/P ≥ 3 for bPEI 1.8kDa and bPEI 25kDa, or at N/P ≥ 6 for DOPE-PEI (Fig. 3.4B). The 
slightly higher N/P ratio for transition from negative to positive ξ-potential for DOPE-PEI reflects 
the altered condensation properties of this vector due to the lipid conjugation. 
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Figure 3.4. Size and ξ-potential as a function of N/P ratio. Scatter symbols represent polydispersity for the corresponding polyplex. A. 
Size measured in 10 mM Hepes, 5 % w/v Glucose, pH 7,4 (HBG). B. ξ-potential measured in HBG. Three separate preparations per 
N/P ratio, error bars represent SD. 
3.4.4 Condensation and decondensation properties of the polypolexes 
The balance between cargo condensation extracellularly and dissociation intracellularly is crucial 
for efficient transfection, and previous reports have indicated full condensation of siRNA cargo 
by bPEI 1.8kDa at N/P2 and DOPE-PEI at N/P394. We examined the ability of all three polymers to 
condense siRNA using the PicoGreen exclusion assay as well as gel-shift assays. The differences 
in condensation behavior of the three polymers are depicted in Figure 3.5, which shows that 
bPEI 1.8kDa and bPEI 25kDa reaches full and similar condensation of the siRNA at N/P2 in 
agreement with literature94. In contrast, DOPE-PEI does not reach full condensation until N/P5. 
These results are supported by the gel-shift assays (Supplementary Fig. 3.2) as well as the ξ-
potential measurements (Fig. 3.4B). 
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Figure 3.5. Condensation of siRNA by bPEI 25kDa, DOPE-PEI and bPEI 1.8kDa. Condensation assessed by PicoGreen exclusion 
following addition of increasing amounts of vector to a constant amount of siRNA. The PicoGreen fluorescence intensity for siRNA in 
the absence of any vector was set to 100%. Results are presented as mean of triplicates ± SD. Trend lines are 5 parameter fits. 
Representative of four independent experiments. 
Anionic competition for binding to the vector polymers is one way to assess the strength of the 
siRNA-vector association, and we therefore monitored the heparin-induced release of siRNA or 
decondensation of the polyplexes through the fluorescence intensity of PicoGreen (Fig. 3.6). 
Surprisingly, bPEI 25kDa polyplexes were the most vulnerable to competition from heparin as 
they decondense to a level of 40% PicoGreen accessibility (percentage relative to free siRNA). In 
contrast, bPEI 1.8kDa and DOPE-PEI reaches plateaus of PicoGreen accessibility of only 5% and 
10%, respectively. 
 
Figure 3.6. Heparin induced decondensation of polyplexes. Increasing amounts of sodium heparin was added to the polyplex 
dispersions and incubated for 30 min before PicoGreen assay. The PicoGreen fluorescence intensity for siRNA in the absence of any 
vector was set to 100%. Results are presented as mean of triplicates ± SD. Trend lines are 5 parameter fits. Representative of three 
independent experiments. 
3.4.5 In vitro knockdown studies 
To systematically analyze and compare the performance of bPEI 25kDa, bPEI 1.8kDa and DOPE-
PEI as delivery agents of siRNA, we established the optimum balance between knockdown and 
induction of cytotoxicity in an HT1080pLUC cell line. bPEI 1.8 kDa was unable to suppress 
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expression of luciferase (Fig. 3.7C), while bPEI 25kDa showed efficient knockdown, reaching a 
plateau of maximum knockdown at N/P3 (Fig. 3.7A). Lipid conjugation of bPEI 1.8kDa 
transformed the polycation into an efficient transfection agent reaching a plateau of maximum 
knockdown at N/P16 (Fig. 3.7B). Above these N/P ratios the cytotoxic impact of the polyplexes 
gradually became apparent. We therefore conclude that bPEI 25kDa at N/P3 and DOPE-PEI at 
N/P16 strike an optimal balance between knockdown and absence of cytotoxicity and regarded 
these formulations as optimal. For referencing with Figure 3.1 and 3.2, these N/P ratios translate 
to 0.67 µg/mL (bPEI 1.8kDa and 25kDa) and 5.2 µg/mL (DOPE-PEI) in our in vitro assays, where 
none of the transfection systems show toxicity. 
 
Figure 3.7. In vitro knockdown of luciferase expression. A: bPEI 25kDa, B: DOPE-PEI, C: bPEI 1.8kDa. N = Negative control cells, P = 
Positive control cells (RNAimax), NS = Non-sense siRNA (anti-GFP siRNA). Cells were incubated in serum-free medium for 6 h with 
polyplexes prepared at varying N/P ratios in serum-free medium, washed and incubated in complete medium for 22 h. RLU = relative 
light units. Results are presented as mean of triplicates ± SD. Representative of three independent experiments. 
The results of Figure 3.3-3.7 demonstrate that excess of vector is also necessary in the case of 
siRNA cargo in order to realize the full transfection potential of each vector. However, compared 
to similar experiments with DNA using bPEI 25kDa95, it is notable that the N/P ratio necessary to 
achieve maximum knockdown is much lower with siRNA than DNA cargo (N/P3 vs N/P8, 
respectively). 
As efficient knockdown required use of vector material in excess of what was required for full 
siRNA condensation, we wanted to investigate the role and importance of this vector fraction 
(the “free fraction”) and how the lipid conjugation affected the behavior of the free fraction 
compared to the conventional bPEI 25kDa (Fig. 3.8). This was assessed as the ability of the free 
fraction to improve the knockdown capability of polyplexes formed at the N/P ratio for full 
condensation. We therefore incubated our reporter cell line with fully condensed polyplexes for 
two hours, added free vector, incubated further, washed to remove uninternalized material, and 
incubated to a total of 28 h before analysis of knockdown. 
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DOPE-PEI and bPEI 25kDa differ in the degree to which delayed addition of the free fraction 
results in as large a knockdown as optimal N/P ratios. For bPEI 25kDa, delayed addition of the 
free fraction results in a knockdown, which is statistically identical to the populations that were 
incubated with polyplexes formulated with the optimal N/P ratio (Fig. 3.8A-C). For DOPE-PEI, 
delayed addition of the free fraction increases the knockdown but not to the level of optimally 
formulated particles (N/P16) (Fig. 3.8D-F). This indicates that lipid conjugation does change the 
behavior of bPEI with respect to the mechanism of action. 
 
Figure 3.8. In vitro knockdown of luciferase expression with delayed addition of the excess fraction of vector. A-C: bPEI 25kDa, D-F: 
DOPE-PEI. The cells were incubated in serum-free medium with fully condensed polyplexes for 2 h, followed by addition of the free 
polymer and incubation for 1 h (A and D), 2 h (B and E), or 4 h (C and F) to a total incubation time with polyplexes and polymer of 3, 4 
or 6 h. The cells were then washed and incubated to a total of 28 h in complete medium. Neg = Negative control cells, Pos = Positive 
control cells (RNAimax). For example (A and D): “3h N/P2” and “3h N/P5” = cells incubated for 3 h with fully condensed polyplexes – 
no free polymer added. “3h N/P3” and “3h N/P16” = cells incubated for 3 h with optimally formulated polyplexes – no free polymer 
added. “3h N/P2 (1h N1)” and “3h N/P5 (1h N11)” = cell incubated for 2 h with fully condensed polyplexes, where after free polymer 
was added to a total polymer amount corresponding to optimally formulated polyplexes, the cell were incubated for 1 h, washed and 
incubated until harvest and analysis. RLU = relative light units. Results are presented as mean of triplicates ± SD. Representative of 
three independent experiments. (*) = significantly different by t-test (p < 0.005). 
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3.4.6 Uptake 
To elucidate how the N/P ratio influenced the uptake and concomitant knockdown, and to see if 
polyplexes of DOPE-PEI behaved differently than polyplexes of conventional bPEIs, we 
performed in vitro knockdown assays using radioactively labeled luciferase siRNA (Fig. 3.9).  
The knockdown profiles in Figure 3.9 confirm the trends from Figure 3.8, i.e. a large knockdown 
by RNAimax (85%), bPEI 25kDa at N/P3 (77%) and DOPE-PEI at N/P16 (86%), a small knockdown 
by bPEI 25kDa at N/P2 (34%) and complete absence of knockdown from bPEI 1.8kDa at N/P2 and 
3, DOPE-PEI at N/P5 and uncomplexed siRNA. These observations correlate well with the uptake 
data, to the extent that bPEI 25kDa at N/P3 and DOPE-PEI at N/P16 show relatively high siRNA 
uptake levels compared with very low uptake levels for bPEI 1.8kDa at N/P2 and 3 and 
uncomplexed siRNA. However, considerable complexity is added by the following observations: 
1) bPEI 25kDa at N/P2 consistently induces a significantly higher siRNA uptake than bPEI 25kDa 
at N/P3 (p < 0.001), but bPEI 25kDa at N/P2 induces only a small knockdown, 2) DOPE-PEI at 
N/P5 is taken up to a considerable extent but induces no knockdown, and 3) RNAimax is never 
internalized to more than 2% of the available siRNA but remains as efficacious as DOPE-PEI at 
N/P16 and bPEI 25kDa at N/P3. 
 
Figure 3.9. In vitro determination of siRNA internalization and knockdown of luciferase expression. The cells were incubated with 
polyplexes of the indicated N/P ratio for 6 h in serum free medium. The cells were then washed with PBS, incubated for 22 h in 
complete medium, washed 1x with PBS-heparin, 1x with PBS, and analyzed for both knockdown of luciferase expression and uptake 
of siRNA. Neg = Negative control cells, Pos = Positive control cells (RNAimax), siRNA = cells incubated with siRNA in the absence of 
vector, RLU = relative light units. Results are presented as mean of triplicates ± SD. Representative of three independent 
experiments. (*) = significantly different by t-test (p < 0.001). 
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3.5 Discussion  
Safe and efficacious delivery of siRNA to the cytoplasm of target cells is a prerequisite for 
knockdown of a target gene. Detailed knowledge of the interaction between the vector 
polymers and the siRNA cargo as well as between the polyplexes and the cells is necessary, if 
rational and focused design of siRNA delivery systems shall become possible. PEI has been 
extensively characterized for DNA delivery on the mechanistic level95–97,100. For instance, it has 
been shown that high efficiency is achieved at N/P > 895,100, while full condensation of the DNA is 
reached at N/P3-495,96,101. This indicates an important role of the fraction of vector that is in 
excess of the amount necessary to form the polyplexes, and the excess fraction has been 
speculated to be free in solution or at least only weakly associated to the nucleic acid-containing 
polyplex. siRNA delivery by PEI has been much less studied, but as size and electrostatic density 
of the cargo as well as intracellular compartment and molecular machinery of action differ for 
siRNA in comparison to DNA, it is not possible to directly extrapolate mechanistic results from 
DNA to the delivery of siRNA102. Therefore, the mechanistics of siRNA delivery using bPEI and a 
lipid conjugate of bPEI has been investigated in this study. 
At similar polycation concentrations, fully condensed polyplexes based on DOPE-PEI display 
lower cytotoxicity than fully condensed polyplexes with bPEI 1.8kDa and bPEI 25kDa (Fig. 3.2, 
filled symbols). Further, at the concentrations relevant to our assays, lipid conjugation of bPEI 
1.8kDa does not appear to have increased the inherent cytotoxicity of bPEI 1.8kDa (Fig. 3.1) in 
spite of DOPE having high membrane affinity and fusogenic capability103,104. However, comparing 
polyplexes of bPEI 25kDa and DOPE-PEI at the optimal N/P ratios (Fig. 3.2A and B) shows that 
there is no large beneficial effect of DOPE-conjugation in terms of a reduction of cytotoxicity. 
While DOPE-PEI based polyplexes are less cytotoxic than polyplexes based on bPEI 25kDa at 
corresponding vector concentrations, this benefit is eliminated by the larger amounts of DOPE-
PEI necessary to achieve the same knockdown effect as with bPEI 25kDa. On the other hand, 
DOPE-PEI may have advantageous formulation properties; the hydrocarbon moiety of DOPE-PEI 
could be used to enable formulation into liposomes or establish otherwise impossible lipid-lipid 
interactions as described by Sawant et al. with DNA cargo72. 
One aspect where DNA and siRNA polyplexes formed using bPEI differ is the stability against 
polyanions such as heparin; siRNA polyplexes with bPEI 25kDa are much more sensitive to 
heparin mediated decondensation than siRNA polyplexes with bPEI 1.8kDa and DOPE-PEI. This 
was surprising since we have observed the opposite for DNA. Here, a heparin:DNA ratio of 10 
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results in 15% decondensation for bPEI 25kDa-polyplexes and 70% for bPEI 1.8kDa-polyplexes, 
showing that bPEI 25kDa-based DNA-polyplexes are far more resistant to heparin-induced 
decondensation than bPEI 1.8kDa DNA-polyplexes (unpublished results). This difference 
between DNA and siRNA is probably due to the smaller size of the siRNA duplexes compared to 
the much larger DNA plasmids. Thus - in the case of siRNA - bPEI 1.8 kDa and DOPE-PEI seem to 
have stronger interactions with the cargo than bPEI 25kDa, possibly due to the higher 
conformational rigidity of the latter105. 
The size measurements in HBG (Fig. 3.4A) demonstrate that all three polycations are able to 
condense siRNA and form particles that are smaller than 200 nm, which is believed to be the 
upper size limit of clathrin-mediated endocytosis106. Furthermore, the ξ-potential 
measurements, PicoGreen exclusion and gel shift assays (Fig. 3.4B, Fig. 3.5 and Supplementary 
Fig. 3.2, respectively) confirm that at the N/P ratio that gives optimal transfection efficiency 
(N/P3 for bPEI 25kDa and N/P16 for DOPE-PEI), excess free vector material is present. In 
addition, the cytotoxicity results (Fig. 3.1 and 3.2) show that the free vector polymers are much 
more cytotoxic than polyplexes containing an equivalent amount of polymer, and that the 
toxicity increases markedly when going from N/P2 to N/P3 for bPEI 25kDa or from N/P5 to 
N/P16 for DOPE-PEI. Combined, these data support that at the optimal N/P ratios two vector 
fractions exist, one that is tightly bound in the core polyplex and one which is less tightly 
associated (a free fraction), each fraction with potentially different functions in the transfection 
process. 
The results demonstrate additional key differences between siRNA and DNA condensation as 
well as differences between the regular bPEIs and the lipid conjugate. Firstly, bPEI 25kDa 
condenses siRNA better than DNA95,97, probably due to the smaller size of the siRNA duplexes 
compared to the DNA plasmid. Secondly, DOPE-PEI reaches maximum condensation at a much 
higher N/P ratio than the free bPEIs. This could be due to polyplex formation having to compete 
with the amphipathic DOPE-PEI’s tendency to self-associate, which would lower the effective 
concentration of DOPE-PEI available for polyplex formation. Alternatively, it could be the 
consequence of DOPE-PEI not being able to pair as many of its charged nitrogens as regular bPEI 
due to its self-association properties and steric hindrance. The idea that lipid conjugation can 
diminish the effective charge of the PEI segment resembles experiences from studies on 
antimicrobial lipopeptides and their partitioning into cell membranes107. 
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The observation that a free fraction of vector is necessary for efficient knockdown, led us to 
examine the role of the free vector. The results from simultaneous determination of knockdown 
and siRNA uptake and experiments with delayed addition of the free fraction, demonstrate the 
complexity of the process of siRNA delivery using bPEI 25kDa and DOPE-PEI as well as further 
important differences between bPEI 25kDa and DOPE-PEI. 
For bPEI 25kDa, the delay experiments indicate that the free fraction is not associated to the 
siRNA-containing polyplexes. This observation is based on the results obtained from adding a 
free vector fraction to cells separately from the fully condensed siRNA-containing polyplexes 
formed at N/P2, where knockdown efficiencies were achieved that were similar to those 
achieved with optimally formulated polyplexes (Fig. 3.8A-C). DOPE-PEI does not fully share the 
behavior of bPEI 25kDa. Even though delayed addition of the free fraction does have a significant 
impact on the knockdown, it does not reach the level of knockdown of optimally formulated 
polyplexes (N/P16) (Fig. 3.8D-F). This is likely due to the amphipatic nature of DOPE-PEI, which 
gives it a tendency to self-associate and results in a different siRNA condensation behavior. 
The siRNA uptake data (Fig. 3.9) demonstrate that the polyplexes based on bPEI 25kDa N/P3 and 
DOPE-PEI N/P16 are internalized to approximately the same extent, corresponding well with 
induction of comparable knockdown in our HT1080 cell line. Conversely, polyplexes based on 
bPEI 1.8kDa are unable to induce knockdown and show only limited uptake, demonstrating that 
lipid conjugation of low Mw bPEI with the intent to increase membrane interaction is a 
constructive strategy71,72. However, a puzzling and mechanistically interesting observation is the 
higher uptake of siRNA by bPEI 25kDa at N/P2 compared to bPEI 25kDa N/P3 (P < 0.001). This 
increased uptake occurs without resulting in a large knockdown. The presented data indicate 
that the free fraction exerts its influence separately from the siRNA-containing core polyplexes, 
and the higher uptake by N/P2 than N/P3 bPEI 25kDa polyplexes suggest that the free fraction 
plays a role after uptake, e.g. by facilitating endosomal escape through the proton sponge 
mechanism. Another possibility is that the free fraction activates an alternate route of uptake 
which bypasses the lysosomal compartment altogether, and thus - while resulting in a lower 
absolute uptake of siRNA - causes the siRNA to be taken up via a route which more efficiently 
directs the siRNA to its intracellular target location. This alternative route could be the proposed 
caveolar pathway87, or it could be another form of internalization such as direct local 
destabilization of the plasma membrane influenced by cross linking of membrane glycoproteins 
and proteoglycans. Such a scenario was recently proposed for lipoplex uptake32 where a small 
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but efficacious uptake of siRNA through a form of direct membrane fusion was hypothesized to 
induce the observed knockdown, while the siRNA taken up through clathrin-mediated 
endocytosis remained trapped in the lysosomes and thus had no effect.  
It is widely reported that bPEI 1.8kDa is inefficient for DNA delivery while bPEI 25kDa is highly 
efficient95, and we confirm this trend for siRNA. Many published reports on DNA transfection 
have compared polyplexes of these two polymers prepared at the same N/P ratio, which should 
provide the two polymers with equal proton-sponge capability. Our data shows that it is the 
internalization step that causes the efficiency gap between bPEI 1.8kDa and bPEI 25kDa, not 
necessarily the ability to induce endosomal escape. This hypothesis is in agreement with the 
work of Navarro and coworkers108, who reported that the use of high N/P ratios and chloroquine 
did not enable bPEI 1.8kDa to induce knockdown. It is likely that it is the interaction with the 
plasma membrane that differs, although the specific mechanism for this membrane interaction 
remains to be elucidated. One structural advantage of bPEI 25kDa over bPEI 1.8kDa could be the 
ability to more efficiently cross-bind multiple anionic membrane proteins on the target cell 
plasma membrane, potentially influencing the uptake process through this interaction. Indeed, 
cross-binding of cell surface receptors has been shown to be able to induce clathrin-mediated 
endocytosis through signaling109,110 and it would be compatible with the uptake improvement 
observed for lipid conjugated bPEI 1.8kDa, since lipid conjugation may increase membrane 
interactions and therefore potentially improve bPEI 1.8kDa’s ability to induce endocytosis. 
Alternatively, it is possible that insertion of the lipid portion of DOPE-PEI into the plasma 
membrane induces membrane invaginations, which may facilitate endocytosis similar to 
observations by Cheng and coworkers111.  
The proton sponge effect has been hypothesized to cause an increase in the pH and osmotic 
swelling of PEI-containing lysosomes resulting in loss of membrane integrity and leakage of the 
nucleic acid cargo into the cytosol55,62. We have previously shown that no change in lysosomal 
pH can be observed for bPEI 25kDa57. However, DOPE-PEI shows different properties and 
behavior, and as the free fraction appears to play a role after polyplex uptake, we investigated if 
the lipid conjugation would change the ability of DOPE-PEI to influence lysosomal pH. We 
measured the pH in the lysosomes of cells exposed to the three vectors, but were unable to 
measure any perturbation of the pH by any of the PEIs compared to the untreated control cells. 
The positive control cells treated with Bafilomycin A1 displayed the expected increase in pH. 
However, even though we do not observe an increase in pH, the PEI polymer could still cause 
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influx of first H+, then Cl- and water but with the V-ATPase being able to compensate and 
maintain the pH in the lysosomes. Osmotic swelling may then cause transient leakage events 
resulting in release of siRNA into the cytosol. The end result would be endosomal escape 
assisted by the proton sponge effect but without a concomitant drop in pH. 
Finally, the efficiency of induced knockdown versus siRNA uptake is much lower for all the tested 
PEI vectors compared to the commercial control, RNAimax. The latter is noticeably more 
efficient than both bPEI 25kDa and DOPE-PEI with an uptake percentage that never exceeds 2% 
(of the siRNA) while inducing a knockdown comparable to bPEI 25kDa and DOPE-PEI. This high 
efficiency is attractive, as less interaction with both siRNA and vector polymers potentially lower 
the cytotoxicity. 
  
3.6 Conclusions 
Our experiments demonstrate the complexity of the cell-polyplex interactions. The importance 
of the free fraction for bPEI 25kDa and DOPE-PEI is evident - in its absence, the vectors are 
substantially less efficient. The considerable uptake of polyplexes of bPEI 25kDa at N/P2 and 
DOPE-PEI at N/P5 without concomitant knockdown indicates that the most important role of the 
free fraction is after internalization. Regardless of the specific role of the free fraction, future 
development of delivery systems for siRNA should consider the presence and potential role of a 
free vector fraction and how this can be controlled for in vivo delivery purposes. Lipid 
conjugation of bPEI 1.8kDa does not in itself provide the solution to the high cytotoxicity of bPEI 
25kDa or the low efficiency of bPEI 1.8kDa. However, DOPE-PEI’s ability to form lipid-based 
interactions may enable it or a similar compound to be formulated into e.g. liposomes that can 
have in vivo transfection potential.  
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3.7 Supplementary Figures 
 
 
 
Supplementary Figure 3.1. Phase contrast images of HT1080pLUC cells exposed to pH-nanosensor and/or different bPEIs. HT1080 
cells were either treated with nanosensor for 16 h (+Nanosensor) or left without nanosensor (÷Nanosensor) for the same time. Cells 
with and without nanosensor were then treated with either of the following PEIs: bPEI 1.8kDa, bPEI 25kDa or DOPE-PEI for up to 6 h 
or left untreated, followed by washing and incubation up to 24 h. Phase contrast images were captured of the cells after 2, 6, 10 and 
24 h. Scale bars, 75 µm. 
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Supplementary Figure 3.2. Condensation of siRNA by bPEI 25kDa (A), DOPE-PEI (B), and PEI 1.8kDa (C), visualized by gel 
electrophoresis. Identical amounts of siRNA in all lanes. The numbers below the lanes refer to N/P ratios, 0 = free siRNA, M = MW 
marker. 
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4 Concluding remarks on Project I 
Project I demonstrates some fundamental challenges facing siRNA delivery using polycations 
such as the bPEI 25kDa and DOPE-PEI. Both vectors are crucially dependent on the co-delivery of 
a free vector fraction to efficiently induce knockdown. Project I indicates that the free fraction 
exerts its influence quite independently of the fraction used for siRNA condensation, with this 
effect being clearest for the conventional bPEI 25kDa. Further, while lipid conjugation of PEI may 
introduce new formulation opportunities, Project I illustrates that cytotoxicity remains a 
challenge.  
The need for controlled co-delivery of the free fraction necessitates some form of spatially 
restricted delivery vehicle which can encapsulate the core polyplex and the free fraction and 
provide this co-delivery capability. The extension of the delivery system with an encapsulating 
vehicle might also provide the opportunity to functionally separate the bound and the free 
vector fraction and enable the use of low MW PEI for siRNA condensation, which would be 
attractive in an effort to minimize cytotoxicity. Furthermore, as Project I demonstrates that the 
poor performance of bPEI 1.8kDa could be due to poor uptake rather than a proven inability to 
facilitate endosomal escape, an encapsulating vehicle might present an opportunity to eliminate 
the use of high MW PEI for transfection altogether. 
On the other hand, it might also be possible to find a better lysosomotropic agent than free 
polycation. More importantly, cationic lipids are able to condense nucleic acids themselves. In 
project I, Lipofectamine® RNAiMAX even compared favorably with polycation-based polyplexes 
in terms of induced knockdown per internalized amount of siRNA. As the latter indicate that a 
higher fraction of the siRNA delivered by cationic lipids reaches the cytosol than is the case for 
siRNA delivered by PEI or DOPE-PEI, Lipofectamine® RNAiMAX may either be internalized by 
another route, more efficient at facilitating endosomal escape or otherwise superior 
downstream of internalization. To conclude, rather than developing a delivery system based on 
encapsulated siRNA-PEI polyplexes, it might be more straightforward to base a delivery system 
on cationic lipids, which would likely reduce the complexity of the delivery system. 
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5 Background  
5.1 Cancer immunotherapy - concept and current state 
With gene therapy realistically being some years from reaching the clinic and traditional 
chemotherapeutics by nature showing low discrimination between malignant and healthy cells, 
much faith has been put into cancer immunotherapy both as a stand-alone treatment strategy 
and in combination with other types of treatment. 
This optimism rests on the advances in general immunobiology and tumor immunology, which 
have made it clear that in many cases the tumors are recognized by the immune system as 
pathogenic growths in spite of the limited difference between the tumor cells and the host 
tissue. Consequently, the host immune system usually attempts to mount an immune response, 
which for a variety of reasons is ineffective at eliminating the tumor112. 
While the concept of manipulating the powerful and highly specific immune system for 
treatment of cancer has been considered extremely attractive for a long time113, the practical 
implementation has been slow, partly owing to insufficient understanding of the complexity of 
the immune system as well as tumor biology.  
The first clinically used therapies, which could claim to be immunotherapies, were the passive 
transfer of anticancer monoclonal antibodies and donor T cells, the latter in the context of 
allogeneic bone marrow transplantation. Both strategies have shown good efficiency in the 
treatment of a variety of malignancies114 and the current arsenal of therapeutic anticancer 
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antibodies (Abs) comprises 14 distinct molecules targeting 9 different antigens, with many more 
in clinical trials115. While studies have indicated that the therapeutic Abs also stimulate adaptive 
immune responses in some settings, they mainly work through interference with oncogenic 
pathways4. Therefore, although both Ab therapy and allogeneic bone marrow transplantation 
reflect the ability of the donor cells or Abs to induce an immediate immune reaction against the 
cancer and are a testament to the power of the components of the immune system, these 
therapies are usually not considered “real” immunotherapies. The active stimulation of specific 
and durable antitumor immunity has proved to be a more challenging objective, the notable 
exception from the numerous failures being intravesical injection of live bacillus Calmette-
Guerin used in the treatment of superficial bladder cancer116. 
5.2 Mechanisms of cancer immunity and opportunities for intervention 
To achieve an anti-cancer immune response, three key actions must be performed by the 
components of the immune system (Fig. 5.1): 
1. Antigen-presenting cells (APCs), i.e. dendritic cells (DCs), must sample tumor derived 
antigens under activating conditions 
2. Activated DCs must generate cancer specific T cells 
3. Cancer-specific T cells must enter the tumor tissues and perform their functions in 
cooperation with activated macrophages 
 
Figure 5.1. Overview of the fundamental steps involved in generation of antitumor immunity. 1: TAAs are sample by DCs. In the 
presence of sufficient co-stimulatory signals DCs mature and migrate to draining lymph nodes. 2: Antigen is (cross)-presented by 
matured DCs, which are able to stimulate naive adaptive effector cells. 3: Activated, TAA-specific adaptive effector cells migrate to 
the tumor tissues and eliminate the malignant cells. Adapted from117. 
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Each of these three steps represents monumental challenges for the immune system. Tumor-
associated antigens (TAAs) do exist and may for instance reflect one or more of the many 
mutated proteins that are typical of the cancer or the products of non-mutated genes that are 
preferentially expressed by cancers. However, they may not be sufficiently abundant or 
immunogenic114. If TAAs are ingested in sufficient quantity by the DCs, the crucial second signal – 
such as stimulation of the DCs through Toll-like receptors (TLRs) or CD40 – may be absent. This 
will result in insufficient activation/maturation of the DCs and tolerance rather than migration to 
the lymph node and presentation of the ingested antigen. If the DCs migrate to the lymph node 
and present the ingested antigen and the maturating stimulus was insufficiently potent and 
failed to induce the crucial co-stimulatory surface molecules on the DCs, interaction with the T 
cells will result in anergy, T cell deletion or the production of regulatory T cells. Finally, if cancer-
specific T cells are generated, they must enter the cancerous tissues to perform killing of the 
malignant cells, which is where the tumor-induced immunosuppressive microenvironment 
returns as a major obstacle. For instance, tumors may down-regulate their expression of MHC I 
molecules and promote accumulation of regulatory T cells in the tumor tissue, thus inhibiting 
the function of T-cells. Tumors produce a variety of surface molecules, which engage receptors 
on the T cells (receptors which are normally intended to keep the immune response from 
running rampant), and induce T cell anergy or exhaustion. Tumors can release 
immunosuppressive mediators such as indoleamine 2,3-dioxygenase and can secrete or induce 
the secretion of the immunosuppressive cytokine IL-10. Finally, tumors can recruit myeloid-
derived suppressor cells, a cell-type distinct from tumor-associated macrophages (TAMs) and 
DCs, which secrete a specialized set of immunosuppressive mediators118.  
While all of the above represent major challenges to the immune system, step 1 to 3 are also 
possible targets for therapeutic intervention. 
Step 1. 
TAAs may be delivered exogenously as part of a therapeutic vaccine, which must comprise co-
delivery of a sufficiently strong maturation signal for the tumor-infiltrating DCs to be activated. 
Such an activation signal could consist of TLR agonists or CD40 Abs. The understanding of DC 
activation has advanced greatly in the last decade and many initial attempts were compromised 
by the absence of an effective DC-activating adjuvant119. A recent promising improvement 
involves the use of 20-mer peptides, which are longer than the 10-12-mers that fit in the MHC I 
molecules; these peptides are thought to be more efficient at generating effector T cells, 
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possibly because some level of processing is benificial120. Full-length proteins are also being 
explored as targets for cancer vaccinations, as they potentially contain a broader profile of 
epitopes121. 
Another strategy for therapeutic vaccination is the cell-based approach, for instance DC-based 
vaccines. Here, DCs are isolated from a cancer patient, loaded with antigens ex vivo, activated 
and re-infused into the patient122. Provenge®, which is an example of this strategy and is based 
on the ex-vivo manipulation of peripheral blood mononuclear cells (PBMCs), was the first cancer 
therapy known to actively manipulate the immune system to receive FDA approval (in 2010). 
However, the strategy is somewhat inhibited by the complexities and costs associated with cell 
isolation, ex vivo manipulation and re-infusion.   
Step 2. 
In the lymphoid organs, TAA-loaded, activated DCs must generate protective T cell responses123. 
The precise type of T cell response needed for successful antitumor immunity is not currently 
known in full detail, but potent induction of CD8+ T cells is assumed to be crucial, although 
responses based on Abs and NK cells may also contribute to tumor immunity. Accordingly, the 
lymph node is a potential site for therapeutic intervention e.g. by providing help to guide the T 
cell activation in the direction of CD8+ T cells, by inhibiting regulatory T cell expansion caused by 
insufficiently matured DCs or by boosting the activation level of the Ag presenting DCs124. 
Step 3. 
Irrespective of the lymphocyte response generated in the lymph node, all effector cells must 
overcome the point immune suppression potently induced by the tumor in the tumor 
microenvironment. Recent years have seen several attempts aimed at overcoming this hurdle. 
Two recombinant cytokines have been approved by FDA for cancer treatment, namely 
recombinant IL-2 (Proleukin™) and IFNα (RoferonA™, IntronA™), each with the potential to 
stimulate adaptive antitumor responses. In addition, recent years have seen the emergence and 
FDA approval of the checkpoint blockers, specifically the recent approval of Ipilimumab (March 
2011, a CTLA-4 specific Ab), Pembrolizumab (Sep. 2014, a PD-1 specific Ab), and Nivolumab (Dec. 
2014, a PD-1 specific Ab). While these drugs are also just monoclonal Abs, they target immune 
mechanisms, which have been confirmed to involve the modulation of endogenous T cell 
responses125. Both CTLA-4 and PD-1 are known to be key negative regulators of T cell activity and 
are expressed on the plasma membrane of T cells in order to control the immune response and 
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prevent excessive activity. However, several cancers appear to be able to hijack these two check-
point systems for their own protection, and abrogation of this hijacking has proven a promising 
strategy. 
5.3 Dendritic cells and macrophages in cancer immune therapy 
As described above, much focus has been placed on tumor-specific CD8+ T cells, their generation 
and tumor-mediated suppression. However, myeloid cells such as myeloid DCs (mDCs) and 
macrophages, as wells as plasmacytoid DCs (pDCs) are also highly involved in the antitumor 
immune response (or its absence) and are crucial in shaping the tumor microenvironment in a 
pro- or anti-tumorigenic direction. 
5.3.1 Dendritic cells in cancer 
Without the efficient antigen-presentation by activated DCs to naive T cells in the lymph nodes, 
no endogenously generated T cells will emerge. In addition, when properly stimulated, mDCs 
and pDCs are important sources of crucial cytokines which potently stimulates anti-cancer 
immune responses. 
pDCs originate in the bone marrow from both myeloid and lymphoid progenitors126. The details 
of their development are incompletely understood, but they are generally regarded as less 
efficient APCs than myeloid DCs, although the specific conditions appear to have a large 
impact127. However, upon registration of viral infection, pDCs are rapidly induced to secrete 
large amounts of IFNα which has stimulating effects on monocytes, NK cells, T cells, B cells and 
mDCs127,128. The most important consequences of IFNα secretion are increased expression of 
costimulatory and MHC molecules on monocytes and mDCs, secretion of chemokines that 
attract other immune cells to the site of injury and increased antigen cross-presentation. While 
all of these actions are attractive for efficient cancer immunotherapy, cross-presentation is 
crucial. Cross-presentation is the display by APCs of endocytosed material on MHC I molecules, 
as opposed to the “normal” practice of presenting extracellular material on MHC II. This is an 
important aspect, as MHC I-mediated presentation is required for the generation of CD8+ T cells 
with the capacity for direct cell killing in an antigen-specific manner. However, the TAAs are 
available as ingestible particles, and are thus directed towards MHC II-based presentation. This 
favors the generation of Th2 cells and skews the immune response in the direction of antibody 
(Ab) production, which is generally accepted to be far less efficient in combatting cancer. 
Myeloid cells with the dendritic cell phenotype can arise in the tumor tissues either as a result of 
extravasation of immature dendritic cells from the blood or through extravasation and 
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maturation of monocytes to inflammatory mDCs, which are thus monocyte-derived129. In the 
tumor tissue, myeloid DCs are able to ingest tumor-associated antigens through the capture of 
dying tumor cells and through the “nibbling” of live tumor cells117. Importantly, mDCs are major 
sources of the cytokine IL-12p70, which is a potent inducer of interferon-γ (IFN-γ) production 
from T cells, NK cells and other cell types, and have also been shown to promote the generation 
of Th1 cells, which support polarization of the immune responses towards a major CD8+ T cell 
component130. Recent evidence even suggests that mDCs themselves may be able to provide a 
boost of IFNγ-secretion when activated, thus contributing to the activation of macrophages as 
well as establishing an autocrine activation loop131. 
mDCs are regarded as the most efficient APC generally, but controversies remain regarding 
which type of DC that represents the best target for cancer immunotherapy132 in light of the 
need for cross-presentation. Reports indicate that while mDCs can cross-present antigen, they 
do so with low efficiency132. On the other hand, the CD141+ DC subset appears to be extremely 
efficient at cross-presenting antigen, but they are very rare, constituting ca. 0.03% of the 
PBMCs133. Further, recent reports suggest that pDC activation is attractive not only because 
secreted IFNα stimulates cross-presentation, but also because pDCs themselves are highly 
capable of cross-presenting antigen under certain conditions134–136. Finally, the inflammatory DCs 
that arise by differentiation from monocytes have also been associated with increased ability to 
cross-present antigen132.  
Unfortunately, while mDCs have been shown to infiltrate cancerous tissues in substantial 
numbers137,138, many studies have documented that the infiltrating DCs become functionally 
impaired due to tumor-derived stimuli. For instance, tumors can prevent antigen presentation 
by switching the differentiation of monocytes to macrophages rather than inflammatory DCs139. 
Tumors also produce glycoproteins, which become confined to early endosomes when 
endocytosed by mDCs, thus interfering with the processing and presentation of the proteins to T 
cells140. Tumors can influence the maturation of mDCs. They can inhibit mDC maturation directly, 
for instance through secretion of IL-10, which results in antigen-specific anergy141,142. Tumor-
derived factors can alter the maturation of mDCs and yield cells that indirectly promote tumor 
growth by favoring the generation of Th2 cells. Promoting the generation of Th2 cells has thus 
been shown to accelerate breast tumor development through the secretion of IL-4 and IL-
13143,144, which are cytokines that prevent tumor cell apoptosis and indirectly promote the 
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proliferation of tumor cells by stimulating tumor-associated macrophages to secrete epidermal 
growth factor.  
5.3.2 Macrophages in cancer 
Macrophages also play an important role in tumor progression and consequently represent a 
potential target for cancer immunotherapy. Circulating monocytes infiltrate the tumor tissues145 
where they may differentiate into inflammatory mDCs, myeloid-derived suppressor cells 
(MDSCs) or macrophages. Macrophages are the major differentiation product when monocytes 
infiltrate cancers146, and tumor associated macrophages (TAMs) have been found to constitute 
up to 50% of the tumor mass147. Cytokines and surface-anchored molecules present in the tumor 
microenvironment influence the differentiation of the TAMs into broadly speaking two polarized 
phenotypes, termed M1 and M2. M1 TAMs, which are considered the classically activated 
macrophages, are stimulated by the presence of IFNγ and produce pro-inflammatory and 
immunostimulatory cytokines such as IL-12p70. However, it is generally observed that most of 
the TAMs are polarized towards the M2 phenotype, which is activated by Th2 cytokines (e.g. Il-4, 
IL-10 and IL-13)147. These M2 TAMs play a pro-tumorigenic role favoring cancer growth. They 
attempt to restore the tumor tissue integrity by promoting angiogenesis as they would for tissue 
remodeling following local injury148, they suppress CD8+ T cell proliferation, and they generate a 
tumor-favorable microenvironment by secreting biochemical mediators that promote cancer cell 
survival, proliferation, and eventual metastasis149.  
5.3.3 Myeloid-derived suppressor cells 
A final cell-type, which contributes to the inadequate immune response to tumors, is the 
myeloid-derived suppressor cell (MDSC)150–152. Although described for the first time more than 
20 years ago in cancer patients, their importance for tumor progression has only become clear 
within the last decade. They are known to be potent suppressors of various T cell functions, 
partly in a contact-dependent manner. In addition, it has been established, that they are a 
heterogeneous population of cells, consisting of myeloid progenitor cells and immature myeloid 
cells. Due to a specific set of surface markers, MDSCs can be distinguished from normally 
differentiated monocytes, macrophages or DCs as well as M2 TAMs153. Further, studies have 
shown that about one third of this population can differentiate into mature macrophages and 
DCs in the presence of the appropriate cytokines in vitro and in vivo151,154. Accordingly, efforts to 
re-program MDSCs are ongoing, and reports point towards vitamin A metabolites being able to 
promote differentiation of MDSCs into mature myeloid cells155.  
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5.4 Macrophages and DC as targets of cancer immunotherapy 
Due to the pivotal roles of monocytes, macrophages and dendritic cells in cancer, they constitute 
attractive targets for cancer immunotherapy, because whatever generated immune effector 
cells will have to work in the tissue microenvironment and be able to function under the 
stimulatory conditions present here. Accordingly, providing activated macrophages and DCs with 
anti-cancer functionality has become a major goal in cancer immunotherapy. 
As described above, DC-based vaccines with ex vivo generation of activated antigen-presenting 
mDCs have been the subject of much experimentation, and the approval of Provenge™ shows 
that in some cases this strategy is feasible. However, due to the cost and complexity of this 
approach, investigators have turned their attention to the strategy of in vivo activation of 
desirable cellular subsets or elimination of unwanted ones156. 
Several strategies exist for the activation of the immune cells. Inhibition of the tumor-induced 
deactivation of T cells is described above, as is the administration of recombinant cytokines IL-2 
and IFNα. A third approach is the stimulation of leukocyte subsets in a manner that mimics 
nature, namely by activating pattern recognition receptors (PRRs). 
PRRs are soluble or cell-anchored molecules, which recognize conserved molecular patterns 
typical of invasive pathogens such as bacteria or virus, and are vital for activation of complement 
and coagulation cascades, opsonization, phagocytosis, apopotosis and induction of pro-
inflammatory mediators. One of the most important classes of PRRs is the Toll-like receptors 
(TLRs)157. 
5.4.1 Toll-like receptors 
TLRs are membrane glycoproteins with an external antigen recognition domain and a 
cytoplasmic signaling domain. 10 functionally distinct TLRs have been identified in humans 
although a ligand for TLR10 has yet to be discovered157. The TLRs show differential expression on 
leukocyte subsets as well as differential subcellular location: TLR1, 2, 4-6 and 10 are surface 
expressed, whereas TLR3 and 7 - 9 are expressed in intracellular compartments, notably in the 
endosomes158–160. The TLR ligands fall into three broad categories: lipids and lipopeptides 
(TLR2/TLR1; TLR2/TLR6; TLR4), proteins (TLR5) and nucleic acids (TLR3, 7, 8, 9)158, and the 
responses to TLR signaling can include cell differentiation, proliferation or apoptosis, as well as 
induction of many secreted mediators, prominently IFNs, TNFα, IL-1, IL-6, IL-10, IL-12, as well as 
a variety of chemokines. In cancer immunotherapy, the interest has focused on the intracellular 
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TLRs, particularly TLR7-9, as they are believed to be responsible for the detection of viral 
infection, thus stimulating immune responses favoring direct killing of infected cells. 
5.4.2 Toll-like receptor agonists 
Owing to the interest in exploiting TLR-mediated activation both to improve the efficiency of 
modern subunit-based vaccines and in cancer immunotherapy, a large amount of TLR7-9 
agonists has been synthesized and are being evaluated both in experimental settings and in 
clinical trials161,162. However, as of 2014 only two drugs with known TLR agonistic mode of action 
are used in the clinic for cancer treatment, namely the previously mentioned bacillus Calmette-
Guérin (an attenuated strain of Mycobacterium bovis originally developed as a vaccine against 
tuberculosis and a potent stimulator of TLR2 and 4) and the TLR7 agonist Imiquimod (Fig. 5.2C). 
While only used topically, Imiquimod has become the “gold standard” against which all newly 
synthesized TLR7 agonists are compared. 
 
Figure 5.2. Examples of imidazoquinoline-based TLR7 agonists163. A. The purine nucleobase Adenine. B. Generic imidazoquinoline. C. 
Imiquimod. D. Resiquimod (R848). 
Imiquimod is an imidazoquinoline (Fig. 5.2B), a class of compounds where several members have 
shown strong TLR 7/8-stimulating potency. As the pharmaceutical properties of Imiquimod and 
the more potent Resiquimod (Fig. 5.2D) prevents systemic administration, newer 
imidazoquinolines have been developed161,164, some of which are currently being tested in phase 
II clinical trials165. 
Another promising class of TLR7 agonists is the guanine analogs166,167 (Fig. 5.3), some of which 
have shown improved efficiency as TLR7 agonists compared to Imiquimod. As one of the major 
barriers to immunotherapy based on systemically administered TLR agonists is the risk of 
inducing potentially toxic cytokine syndrome168,169, one group of researchers conjugated such a 
guanine-like TLR7 agonist to mouse serum albumin by the rationale that stable conjugation to a 
macromolecule, such as a protein, would restrict systemic absorption170. They observed a 10-100 
fold increased potency compared to the free drug171 and were able to achieve efficient delivery 
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to the respiratory system without induction of systemic cytokine syndrome in two mouse 
models of pulmonary infectious disease171. 
 
Figure 5.3. Examples of guanine-analogues with TLR7 agonist activity163,172,173. A. The purine nucleobase Guanine. B. Loxoribine. C. 
UC-1V150. D. TMX-202. 
Further, as TLR7 is expressed in the endosomes and conjugation of various chemical entities to 
phospholipids has been shown to facilitate endocytosis170, the same group investigated the 
impact of conjugating the TLR7 agonist to phospholipids172,173, and structures of their lipid 
conjugates are shown in Figure 5.3C and 5.3D. They observed increased potency of the lipid-
conjugate in human PBMCs compared to the unmodified TLR7 agonist and also saw prolonged 
increases in the levels of pro-inflammatory cytokines in serum when the lipid-conjugate was 
administered to mice in a systemic fashion172. No observations were made as to whether the 
cytokine syndrome could also be prevented by the lipid-conjugation under the conditions of 
systemic delivery. 
5.4.3 Targeted delivery 
While the conjugation of the receptor-interacting entity to a macromolecule is one way to 
achieve some level of targeting to phagocytic cells, a much more focused and versatile way to 
achieve targeted delivery is through the use of Ab- or protein-conjugated liposomes. While 
direct conjugation of the drug to a targeting ligand employs the same fundamental mechanism, 
targeted liposomes are theoretically superior since a relatively low number of targeting ligands 
are needed to deliver a large number of drug molecules, thus ensuring efficient and potent 
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receptor-agonist interaction. If the drugs are encapsulated, the liposomes are also able to 
protect the drugs from degradation in the bloodstream174. 
Liposomes themselves are versatile carriers of drugs and contrast agents, and are extensively 
used in drug delivery research, often to ameliorate the side effects of traditional cancer 
therapeutics. As of 2013, nine liposome-based drugs have received FDA approval and many are 
showing promising results in clinical trials175. Their attraction lies in their composition; as they 
consist of an aqueous core entrapped by one or more bilayers composed of natural or synthetic 
lipids, they are completely biocompatible and biodegradable, and they possess low intrinsic 
toxicity176. 
Liposomes were first described by Bangham177 in 1964, while the idea to use liposomes as drug 
delivery vehicles is normally attributed to Gregory Gregoriadis178. However, the implementation 
of this idea was for a long time hampered due to extensive interaction with the complement 
system and rapid clearance by the MPS system, which could not be eliminated by the use of 
saturated phospholipids and cholesterol alone. However, in 1991 it was discovered that 
decoration of the liposomes with a hydrophilic polymer such as PEG could dramatically increase 
the circulation time of the liposomes. The dominant underlying mechanism for this extended 
circulation is believed to be the flexible PEG chain occupying the space immediately adjacent to 
the liposome surface (“periliposomal layer”), thus excluding other macromolecules from this 
space179. Consequently, access and binding of blood plasma opsonins to the liposome surface 
are hindered and interaction with the MPS is minimized. 
5.4.4 Immunoliposomes 
Another highly attractive aspect of liposomes is the relative ease of surface modification, 
through conjugation to the lipid head groups. Consequently, liposomes have been modified with 
a wide variety of ligands174 and one of the most popular modifications for targeted delivery is the 
conjugation of Abs or Ab fragments to the liposomes, which are then often referred to as 
immunoliposomes. The best described use of immunoliposomes is for treatment of cancers, e.g. 
HER2/neu positive breast cancer. However, for treatment of solid cancers, conjugation of Abs to 
the liposomes will usually not in itself lead to increased accumulation in the tumor 
microenvironment as this process remains dependent on the passive accumulation of liposomes. 
Rather, the Abs will provide an advantage after exit of immunoliposomes from the bloodstream, 
where they will facilitate sequestration in the tissues as well as potentially the uptake. 
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Procedures for preparation of immunoliposomes are well-described in the literature and can be 
separated into two general strategies: post-insertion and post-functionalization (Fig 5.4). In the 
post-insertion approach, the Abs are covalently coupled to preformed lipid-PEG micelles, which 
have a reactive functionality in the distal end of the PEG that allows coupling of the Ab. 
Subsequent incubation with preformed liposomes allows the lipid-Ab conjugates to transfer 
from the micelles into the outer liposomal membrane, if the process is otherwise 
thermodynamically favored. Post-functionalization of liposomes with Abs is carried out using the 
same basic ingredients, but here the liposomes are prepared comprising the lipid, which on the 
surface of the liposomes displays the linker. Upon incubation of these “surface reactive” 
liposomes with the Ab, the Ab is tethered to the liposome surface. In cases where the liposomes 
are loaded with drugs in the aqueous lumen, the decoupling of the conjugation from the 
liposome formation can be an advantage. In addition, post-insertion allows easier fine-tuning of 
the number of Abs on display on the liposomes surface and upscaling is also easier. However, 
separation of the prepared immunoliposomes from the micelles can be troublesome. On the 
other hand, post-functionalization allows straightforward separation of the immunoliposomes 
from the un-conjugated protein, although the yield of post-functionalization is often lower. The 
latter is probably due to inherent instability of the reactive linker combined with a somewhat 
extended procedure as well as the fact that reactions that work well in solution may proceed 
very slowly on a surface and not go to completion174. 
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Figure 5.4. Cartoon representation of Ab functionalization of liposomes by post-functionalization (A) or post-insertion (B) 
approaches. A. PEGylated liposomes are prepared, which on the distal end of the PEG expose a reactive linker (blue segment) and 
are then mixed with Abs, which are suitably preconditioned for reaction with the linker. B. PEGylated liposomes are prepared, and 
Abs are covalently coupled to preformed lipid-PEG micelles through a reactive linker. Upon mixing of the PEGylated liposomes and 
Ab-conjugated micelles, Ab-conjugated lipids may transfer from the micelles to the liposomal membrane.  
5.4.5 Targeting monocytes, macrophages or DCs 
Clearly, a deciding parameter in Ab-based delivery is selection of a suitable target. The antigen 
must be differentially expressed on the target cells as well as have high surface expression to 
ensure efficient association of the immunoliposomes. Further, a specific Ab with high affinity 
must be available. For the purpose of delivering compounds to monocytes, macrophages or 
dendritic cells, C-type lectin receptors (CLRs) have been popular antigenic targets180–182. 
The CLRs is a large class of receptors, in which the members are united by their ability to 
recognize specific carbohydrate moieties through their carbohydrate-binding domain (CRD). In 
humans, the CLRs perform a variety of functions such as facilitating adhesion between cells, 
adhesion of cells to the extracellular matrix, or acting as PRRs. Depending on the specific 
function of the CLR, ligand recognition can induce a variety of cellular responses, and accordingly 
CLRs can be functionally divided into those that inhibit or those that induce cellular activation. 
Some CLRs are known to function as antigen-uptake receptors with CLR-mediated antigen 
uptake leading to efficient antigen presentation and immune stimulation183,184. As 
immunoliposomal drug delivery (whether the intent is elimination or stimulation of the cell) is 
often facilitated by internalization, selecting CLRs as targets for immunoliposomal delivery to 
A
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myeloid cells may thus be an attractive strategy. However, as activation of the C-type lectins 
may have a profound functional impact on the cell, careful selection is necessary185,186. 
The Dectin-2 cluster of CLRs contains Dectin-2 (CLEC6A), DCIR (CLEC4A), DCAR, BDCA-2 (CD303), 
which are all member of the Group II family of C-type lectins. BDCA-2 is the best known member 
of the group, as it is frequently used as a specific marker for plasmacytoid dendritic cells. In 
contrast, Dectin-2 and DCIR surface expression has been detected on multiple leukocyte 
subsets187–189, while DCAR protein expression remains un-characterized190. BDCA-2, Dectin-2 and 
DCIR are examples of CLRs that have been shown to be endocytosed as a result of cross-linking, 
thus potentially constituting targets for delivery of drugs to the populations.  
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6 Aim of Project II 
The aim of project II was to prepare immunoliposomes capable of targeting monocytes, myeloid 
dendritic cells and plasmacytoid dendritic cells. For this purpose, the antigen target was chosen 
to be the Dendritic Cell Immunoreceptor (DCIR), which is highly expressed on the surface of 
monocytes and mDCs as well as showing some expression on pDCs and B-cells. Further, the 
project aimed to test if the targeted delivery of a TLR7 agonist to monocytes, myeloid dendritic 
cells and plasmacytoid dendritic cells using the developed liposomal platform could activate the 
targeted cells. Finally, the project aimed to investigate if the targeted liposomal delivery of the 
TLR7 agonist would increase the potency of the agonist with respect to activation of the targeted 
cells. The activation of the targeted cells was evaluated by measuring the secretion of selected 
pro-inflammatory cytokines to the culture supernatants, some of which have been crucially 
linked to successful antitumor immune response. 
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7 Article 2: Activation of dendritic cells and monocytes by 
targeted delivery of a TLR7 agonist 
This section contains the manuscript in preparation for submission to Nanomedicine: 
Nanotechnology, Biology and Medicine. 
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7.1 Abstract 
Targeted delivery of immune modulators to specific leukocyte subsets in the bloodstream is a 
promising approach to increase the efficiency and reduce the side effects of immunotherapy. 
Monocytes and dendritic cells (DCs) are attractive targets for immune response modifiers 
(IRMs), as they have central roles in both innate and adaptive immune responses and play 
crucial roles in shaping the nature of the tumor microenvironment. In this study, we describe a 
liposomal platform for simultaneous targeting of monocytes and DCs in the bloodstream. We 
demonstrate the potential of this platform by delivering a TLR7 agonist to monocytes, myeloid 
DCs (mDCs) and plasmacytoid DCs (pDCs) in PBMC culture. Monocytes and mDCs are targeted 
with high specificity over lymphocytes, and we demonstrate potent induction of the pro-
inflammatory cytokines IL-12p70, TNFα, and IFNα2a. Importantly, we also detect high levels of 
IFNγ, indicating subsequent activation of NK or T cells. This delivery system may be able to 
improve cancer treatment either as a vaccine with co-formulated antigen or by increasing the 
potency of IRMs with respect to activation of monocytes and DCs. 
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7.2 Introduction 
Cancer immunotherapy theoretically offers high specificity and potentially long-lasting 
protection. If the therapy is successful, antitumor immunity leads to production of cytotoxic 
immune cells that can recognize and eliminate cancer cells effectively, as well as generation of 
immunological memory191. 
Advances in tumor immunobiology have demonstrated that the immune system almost always 
has the ability to recognize and attack cancerous cells, despite the cells being very similar to 
normal ‘self’. However, in clinically identified cancer the tumor develops immunosuppressive 
mechanisms that manipulate the immune system and protect the tumor against immune 
surveillance112. 
The tumor-induced immunosuppressive actions severely impair the functionality of 
macrophages and DCs. Tumor tissues are often heavily infiltrated by macrophages (tumor-
associated macrophages, TAMs)147, but the majority of the TAMs adopt an inactive or immuno-
suppressive phenotype, de facto promoting tumor growth and metastasis by supporting matrix 
remodeling, angiogenesis and suppressing antitumor activities192,193. Similarly, while numerous 
studies have concluded that myeloid DCs (mDCs) infiltrate tumors138 and the immune system has 
the ability to recognize and attack cancer cells, tumors often evade detection by down-
regulating antigen presentation and impairing mDC function and migration137,139,142. Finally, due 
to mediators released by the tumor cells, tumor-infiltrating plasmacytoid DCs (pDCs) are 
maintained in a semi-mature state with strongly impaired secretion of IFN-α194. 
Accordingly, a number of strategies aim to provide activated dendritic cells and/or macrophages 
to the tumor tissue, hoping to reduce tumor-mediated immunosuppression and reinstate 
immune surveillance of the tumor. A strategy which has enjoyed some success in clinical trials is 
DC vaccination – the ex vivo activation of autologous mDCs followed by re-administration to the 
patient; however, widespread translation into the clinic is inhibited by the complexity and cost 
of the procedure137. Another attractive strategy is to re-polarize the tumor microenvironment by 
administration of recombinant cytokines or IRMs, e.g. Toll-like receptor (TLR) agonists. 
The reliable detection of pathogenic invasion is crucial to the function of the immune system. 
One strategy is based on the recognition of conserved molecular patterns that are exclusive to 
the microbial world. These are detected by pattern recognition receptors (PRRs) that alert the 
host immune system to the presence of infectious material157. The TLR family is one of the best 
characterized classes of PRRs in mammals158. 10 distinct subtypes exist in man195,196, and ligand 
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recognition and TLR activation have been shown to boost adaptive immune responses 
significantly157. TLR7 is expressed in monocytes, mDCs and pDCs, and B-cells although the 
expression levels remain debated157,172,197. It is localized in the endosomal membrane, where it is 
activated by single-stranded RNA of viral origin198, and has been suggested as an important 
target for future vaccine and cancer immunotherapy199.  
Several commercially available TLR7 agonists exist, more are in clinical development and new 
derivatives are continuously being reported161,200. The TLR7 agonist used in this study is 
designated TMX-202. It belongs to a relatively new class of TLR7 agonists, namely the guanine-
like agonists, and has been shown to potently stimulate mammalian immune cells171,172. 
Liposomes are versatile carriers for a broad spectrum of compounds52,201 and are ideally suited 
as vehicles for the lipid-based TMX-202. Liposomal formulations are currently in use for cancer 
treatment201, primarily for delivery of conventional cytotoxic compounds such as doxorubicin. 
However, tumor-accumulation remains a challenge, partly because it hinges on the enhanced 
permeability and retention (EPR) effect, which varies greatly across cancer types and species, 
often due to insufficient vascularization of hypoxic areas of solid tumors29,202.  
Due to the variability of the EPR effect, it is an attractive and elegant strategy to target leukocyte 
subsets while they are present in the bloodstream, activate/precondition them, and leave the 
egress from the circulation and migration to the tumor to the evolutionarily perfected biological 
mechanisms. As PEGylated liposomes are only minimally cleared from the circulation by the 
mononuclear phagocyte system29,203, one way to theoretically ensure rapid and specific 
association and internalization by leukocyte subsets is decoration of the liposomes with 
antibodies (Abs) against a subset-specific antigen. Abs against the C-type lectin “Dendritic Cell 
Immunoreceptor” (DCIR) is an attractive choice in order to achieve uptake of liposomes by 
monocytes and DCs: DCIR is differentially expressed on leukocytes with high surface levels 
present on both monocytes and mDCs and lower levels present on pDCs and B-cells204. Further, 
it has been shown that binding of the receptor leads to endocytosis of the receptor-ligand 
complex204 thus ensuring optimal conditions for interaction between the TLR7 receptor and a 
TLR7 agonist.  
In the present study, we report a liposomal drug delivery system for robust and specific targeting 
of monocytes and DCs consisting of PEGylated liposomes with surface-conjugated antibodies 
against DCIR. We show that the liposomes effectively target monocytes and mDCs over other 
leukocytes in a PBMC suspension, as well as to a lesser extent pDCs. Further, we show that the 
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targeted delivery of a TLR7 agonist to monocytes, mDCs and pDCs using the presented platform, 
results in significantly upregulated production of pro-inflammatory cytokines in vitro compared 
to the non-sense targeted control and the free agonist. 
We believe that our targeted delivery platform, which enables simultaneous targeting of 
monocytes and DCs, may support future development of cancer immunotherapy by targeting 
peripheral monocytes and DCs with liposomes loaded with immune stimulating adjuvants. 
 
7.3 Materials and Methods 
7.3.1 Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene-glycol)-2000] (DSPE-PEG2000), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-mal), 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DPPE-RhB) 
and cholesterol (Chol) were purchased from Avanti Polar Lipids (Alabaster, AL, USA) and used 
without further purification. 2-(4-{[6-Amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9(8H)-
yl]methyl}benzamido)ethyl 2,3- Bis(dodecanoyloxy)propyl phosphate (TMX202) was kindly 
supplied by Telormedix, Bioggio, CH). 2-iminothiloane (Traut's reagent), 5,5 '-dithio-bis(2-
nitrobenzoic acid) (DTNB) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) as was Ficoll-Paque Premium, PBS, RPMI, 
penicillin (pen), streptomycin (strep), Trypan blue and Human AB serum (heat-inactivated). 
Herceptin™ was kindly supplied by Anders Elias Hansen (Department of Biomedical Sciences, 
University of Copenhagen). Flat-bottom polystyrene 96-well plates (clear and black), round-
bottom polystyrene 96-well plates and 96 well maxisorb™ plates for ELISA were purchased from 
Thermo Scientific (Waltham, MA, USA). Disposable UV micocuvettes, 15 mm center height, were 
purchased from Brand (Wertheim, Germany). Human buffy coats were acquired from the blood 
bank at the National Hospital of Denmark (Rigshospitalet) collected from anonymous healthy 
donors. Blood samples were handled in accordance with guidelines put forward in the 
‘Transfusion Medicine Standards’ by the Danish Society for Clinical Immunology (www.dski.dk). 
All standard chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and they were 
analytical grade. 
 
 
 
66 
 
    Article 2 
 
Antibodies 
Murine anti-human DCIR monoclonal Ab (IgG1) and matching control monoclonal Ab (IgG1 
specific for a non-human epitope) was purchased from R&D Systems (Minneapolis, MN, USA). 
Fluorochrome-conjugated Abs for flow cytometry were as follows: CD16-FITC, CD123-APC, 
CD141-BV510 (BD Biosciences, San Jose, CA, USA); CD14-PE-Cy7, CD3-eFluor450, CD19-eFluor 
450, CD1c-PerCP-eFluor710 (Ebiosciences, San Diego, CA, USA), CD303-APC (Miltenyi Biotec, 
Bergisch Gladbach, Germany), and CD56-Pacific Blue (Biolegend, San Diego, CA, USA). 
7.3.2 Methods 
Preparation of maleimide-functionalized liposomes 
Maleimide functionalized liposomes (m-liposomes) composed of DPPC:chol:TMX-202:DSPE-
PEG2000:DSPE-mal:DPPE-Rhd with mole ratio of 59.70:30:5:4.6:0.5:0.2 were prepared by the 
lyophilization method205. Briefly, the lipids were dissolved in tert-
butanol:isopropanol:ethanol:DMSO at a ratio of 166:1:8:2 to a final lipid concentration of 9 mM, 
mixed thoroughly, frozen in liquid nitrogen and lyophilized to a dry powder over-night. The 
powder was hydrated with 10 mM Hepes, 150 mM NaCl, pH 7.4 (HBS) to a lipid concentration of 
15-20 mM. This solution was incubated at 55 °C for 1 h with stirring and extruded through 
polycarbonate membranes (400, 200, and 100 nm pore size) using an Avanti® mini-extruder in a 
heating block (Avanti Polar Lipids, Alabaster, AL, USA) at 55 °C. 
Antibody thiolation 
Herceptin™ (for process optimization), anti-DCIR Ab, and control Ab were dissolved in 0.2 M 
Borax, pH 8.5 (Borate buffer) to a concentration of 2.5 mg/mL. 2-iminothiloane (Traut’s 
reagent206) was dissolved in the same buffer to a concentration of 0.4 mg/ml. Ab and 2-
iminothiloane were mixed together and incubated at RT in the dark for 1 h, after which the 
solution was ultrafiltrated twice using Borate buffer and Amicon spin filters (30 kDa cut-off, 
Merck Millipore, Billerica, MA, USA). 
Determination of thiolation using Ellman’s reagent 
Thiolation was determined using Ellman’s reagent207,208. Briefly, 2 nmol of thiolated protein was 
added to a disposable cuvette, Borate buffer was added to the cuvette to a total volume of 0.4 
mL, and absorbance at λ = 412 nm was recorded (sample and blank) on a Unicam Helios α 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). 30 µL of Ellman's reagent207 (2 mM 
DTNB in Borate buffer) was added to sample and blank, mixed, incubated at RT for 15 min, and 
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absorbance at λ = 412 nm was recorded. The number of thiols per Ab was calculated using  the 
following formula (ε = 0.0141208): (0.4 x (ΔA / 0.0141) / 2. 
Determination of lipid concentration 
Phospholipid concentrations were measured by inductively coupled plasma mass spectrometry 
(ICP-MS). Liposomes were diluted to a final phosphate concentration of 30-95 PPB in a solution 
of 2% HCl and 10 PPB Gallium, and the phosphate concentration was measured using ICP-MS 
(iCap Q, Thermo Scientific, Waltham, MA, USA). For relative estimates of lipid concentration for 
size exclusion chromatography (SEC), the fluorescence intensity of Rhodamine B was measured 
using excitation and emission wavelengths of 570 and 610 nm on a Victor 3 plate reader (Perkin 
Elmer, Waltham, MA, USA).  
Determination of Ab concentration 
Ab concentration was determined using Coomassie Plus Assay with BGG as reference protein 
(Thermo Scientific, Waltham, MA, USA) with the A595 measurements performed on a Sunrise 
plate reader (Tecan, Männedorf, Schweiz). If the unknown samples contained RhB-labeled 
liposomes, the contribution from RhB was subtracted through measurement on a suitably 
prepared background series of non-Ab-conjugated RhB labeled liposomes. 
Conjugation of thiolated Ab to m-liposomes 
Thiolated Ab and m-liposomes were mixed in a glass vial at a DSPE-mal:Ab mole ratio of 10. The 
air phase was replaced with N2, the bottle capped, and the vial placed on a shaker table for over-
night reaction at RT in the dark. As the conjugation efficiency was strongly influenced by 
maleimide degradation as a function of time209, liposome hydration and extrusion followed by 
Ab thiolation and start of conjugation were performed within 6-8 h. Further, as the conjugation 
efficiency was highly dependent on the pH of the conjugation mixture, the pH of the conjugation 
mixture was always adjusted to 8.5.  
Purification of immunoliposomes 
The Ab-conjugated liposomes were purified by size exclusion chromatography using Sepharose 
CL-4B resin (GE Healthcare, Piscataway, NJ, USA), HBS solvent and a flowrate of 1 mL/min. SEC 
equipment was from Bio-Rad (Hercules, CA, USA). Fraction analysis was performed by 
determination of RhB fluorescence (≈100 µL fraction per well in a dark 96-well plate measured 
on a Victor 3 plate reader and relative Ab concentration in the fractions was determined using 
Coomassie Plus Assay. 
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Calculation of number of Abs per immunoliposome 
For a given solution of immunoliposome: Ab concentration and lipid concentration (Clipid) was 
determined. Ab concentration was converted to number of Ab using Avogadro’s number (NA). 
Liposome concentration (liposomes per mL, NL) was determined using the following formula: NL 
= Clipid x NA /(N x 1000). NA = 6.0x1023, Clipid is the concentration as determined by ICPMS, and N = 
the number of lipids per liposome which is calculated according to the following formula: N = 
17.69/B x [(d/2)2 + (d/2 - 5)2)]. d = outer diameter of the liposomes and B is a correction factor 
for cholesterol, which in a lipid membrane has approximately half the volume of a phospholipid. 
At 30 mole% cholesterol, B = 0.85. 
Size, polydispersity index (PDI) and ξ-potential 
Size (hydrodynamic diameter) and PDI were measured by dynamic light scattering (DLS) using a 
ZetaPALS (Brookhaven Instruments Corporation, Holtsville, NY, USA). ξ-potentials were 
determined using laser-Doppler electrophoresis on the ZetaPALS. Liposomes were diluted to a 
final concentration of ≈1 mM lipid in HBS (size) or 10 mM Hepes, 300 mM glucose, pH 7.4 (HBG) 
and measured after equilibration at room temperature (RT) for 15 min. 
Determination of TMX-202 concentration 
TMX-202 concentration was determined using HPLC and correlating to a standard curve 
comprising the following TMX-202 concentrations (µg/mL): 60, 30, 15, 7.5, 3.75, 1.875, 0.0. A 
Gilson HPLC system (Middleton, WI, USA) fitted with the following column: Xbridge TM C18, 5 
µm, 4.6 x 150 mm (Waters, Milford, MA, USA) was used. All samples were dissolved in 
water:tetrahydrofuran (THF) 1:1. Solvent A: Millipure water with 0.1 % Trifluoroacetic acid (TFA). 
Solvent B: THF with 0.1% TFA. The liposomes were diluted 5x in water:THF 1:1 before the 
injection. HPLC parameters: Starting solvent ratio = 20% B; Ending solvent ratio = 68% B; 
Gradient time = 19 min; Total run time: 25 min; Injected sample volume = 100 µL; UV detection 
at λ = 293 nm; Column temperature = 30°C. 
Separation of peripheral blood mononuclear cells (PBMCs) from buffy coats 
Human PBMCs were isolated from buffy coats of healthy blood donors after informed consent 
using standard Ficoll-Paque density gradient centrifugation. Briefly, the buffy coat was diluted 5x 
with RPMI with 5% pen/strep. 25 mL diluted buffy coat was carefully placed on top of 12.5 mL 
density gradient medium in 50 mL falcon tubes, and the tubes were centrifuged at 500xg for 30 
min at RT without brake. The PBMC fraction was separated and washed 3x with RPMI with 5% 
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pen/strep (centrifugation at 280xg). Finally, all the PBMCs from one donor was resuspended in 
≈20 mL RPMI with 5% pen/strep, stained for vitality using trypan blue and counted. 
In vitro association of anti-DCIR-, control- and m-immunoliposomes with PBMCs 
7 mio PBMCs in 2 mL RPMI with 5% human AB serum and 5% pen/strep (PBMC medium) were 
incubated for 1 h with rotation at 37°C in the presence of free agonist (1 and 10 µM), m-
liposomes (1 and 10 µM), control immunoliposomes (1 and 10 µM) and anti-DCIR 
immunoliposomes (1 and 10 µM) in 2 mL eppendorf tubes. Following incubation the cells were 
washed with RPMI with 5% pen/strep (centrifugation at 300xg, RT) and analyzed for RhB 
positivity using flow cytometry. The normalizing parameter was chosen to be the agonist 
concentration. Accordingly, 1 and 10 µM TMX-202 concentration corresponds to 22.22 and 
222.2 µM lipid concentration for the anti-DCIR immunoliposomes (in the rest of the article 
referred to as DCIR liposomes), 21.66 and 216.6 µM lipid for the control immunoliposomes (in 
the article referred to as control liposomes) and 19.64 and 196.4 µM lipid for m-liposomes.  
Flow cytometry analysis of liposome association to PBMC subsets 
Stimulated PBMCs were stained with a premixed cocktail of fluorochrome-conjugated Abs. 
Briefly, the PBMCs were washed 2x with PBS with 1% heat inactivated FBS, 0,10% (w/v) NaN3 
(FACS buffer) and incubated for 15 min at 4°C in the dark with Fc blocker (FACS buffer with 2 % 
Human Serum). To the cells was then added the premixed cocktail of fluorochrome-conjugated 
Abs, with which they were incubated for 30 min at 4°C in the dark. Then the cells were washed 
2x in FACS buffer and flow cytometry data was acquired using a BD FACS CANTO II (BD 
Bioscience, San Jose, CA, USA) and BD FACS Diva software. Data analysis was done using FlowJo 
software vs 10 (TreeStar, San Carlos, CA, USA). 
The gating strategy (Supplementary Fig. 7.1) divided the PBMCs into 4 subsets: monocytes, 
mDCs, pDCs, and T, B and NK cells. PBMCs were gated on FSC-SSC. T, B and NK cells were 
identified as CD3+, CD19+ or CD56+ (lin+) PBMCs. Monocytes were identified as lin-CD16-CD14+ 
PBMCs. pDCs were identified as lin-CD14-CD16-CD123+. mDCs were identified as lin-CD14-CD123-
CD16-CD1c+ PBMCs. However, comparing the lin-CD14-CD16-CD123+ PBMCs with lin-CD14-CD16-
CD303+ PBMCs (Fig. 3F) revealed that the use of CD123 as a pDC marker led to inclusion of cells, 
which were excluded by the CD303 marker. As CD303 is exclusively expressed on pDCs and is the 
recommended pDCs marker210, we therefore analyzed PBMCs from 2 separate donors but 
substituted CD123 with CD303 as marker for pDCs (same isotype, fluorophore and instrument 
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settings) and constructed a not-gate to exclude lin-CD14-CD16-CD123+CD303- cells from our 
original pDC population (Fig. 3G). Consequently, in our final analysis pDCs were identified as lin-
CD14-CD16-CD123+ PBMCs, which were not excluded by the lin-CD14-CD16-CD123+CD303- not-
gate. We speculate that the lin-CD14-CD16-CD123+CD303- PBMCs might be basophils, as they 
have been shown to express CD123211. 
The gates showing the percentage of RhB positive cells were set based on HBS treated control 
cells without addition of liposome. 
In vitro stimulation of PBMCs 
Based on the available literature on TMX-202 and TMX-202-like compounds administered in a 
non-targeted fashion172,173, we chose a TMX-202 concentration of 1 µM for the stimulation 
experiments. 7 mio PBMCs in 2 mL PBMC medium were incubated for 1 h with rotation at 37°C 
in the presence of free agonist (1 µM TMX-202), m-liposomes (1 µM TMX-202), control 
liposomes (1 µM TMX-202) and DCIR liposomes (1 µM TMX-202) in 2 mL eppendorf tubes. Then, 
the cells were washed with RPMI with 5% pen/strep (centrifugation at 300xg, RT), resuspended 
in PBMC medium plated in round-bottom 96-well cell culture plates (175,000 cells per well, 175 
mL medium per well, 30 wells per population). Cell free supernatants were collected after 
incubation for 1, 2, 3, 4, and 5 days - the supernatants were collected, spun down (400xg, 5 min), 
where after the supernatants were stored at -80°C until analysis for secreted cytokines. 
Analysis of culture supernatants for secreted cytokines 
Cytokine analysis was performed using Meso Scale Discovery’s electrochemiluminescence-based 
multiplex assays following the instructions from the manufacturer. The culture supernatants 
were analyzed for IL-6, IL-10, IL-12p70, TNF-α and IFN-γ using V-PLEX Proinflammatory panel 1 
kit and for IFNα2a using “Human IFNα Ultra-Sensitive Kit”. Both kits were developed on Sector 
Imager 2400, all from Meso Scale Discovery (Rockville, MD, USA). Minimum detection levels 
were: 7.74 pg/mL (IFNγ), 0.69 pg/mL (TNFα), 1.58 pg/mL (IL-6), 0.68 pg/mL (IL-10), 1.22 pg/mL 
(IL-12p70), 0.7 pg/mL (IFNα2a).  
Statistics 
Flow cytometry data are presented as percentages of positive cells based on the uptake of DSPE-
RhB. Association of liposomes to PBMCs and cytokine secretion data were analyzed using one-
way ANOVA and two-tailed T-tests, all non-parametric. 
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7.4 Results 
7.4.1 Preparation of immunoliposomes 
Traut’s reagent was used to thiolate Abs, and initial experiments focused on investigating how 
the average number of thiols per Ab depended on the molar ratio between Traut’s reagent and 
Ab. A linear dependency was found for the thiolation degree as a function of the Traut’s:Ab ratio 
(Fig. 7.1). To minimize potential cross-binding of immunoliposomes mediated by too highly 
thiolated antibodies, while simultaneously maximizing Ab conjugation efficiency, a Traut’s:Ab 
molar ratio of 25 was found to be optimal yielding approximately 1.2 thiols per Ab for both anti-
DCIR Ab and IgG1 control Ab. 
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Figure 7.1. Linearity of thiolation. Ab (Herceptin™) was dissolved in 0.2 mM Borate pH 8.5 at 2.5 mg/mL. 2-iminothilane was 
dissolved to 0.4 mg/mL and immediately added to the dissolved Ab and incubated for 1 h at RT in the dark with shaking. Error bars = 
S.E.M. Results from 2 independent experiments. 
TMX-202 was formulated into maleimide-functionalized liposomes (m-liposomes) and 
conjugated to thiolated Ab by reaction over-night at a molar maleimide:Ab ratio of 10. As the 
thiol specificity of the conjugation reaction at high pH was a concern, reaction specificity at pH 
8.5 was evaluated by conjugating non-thiolated Ab to m-liposomes. No conjugation could be 
detected, which demonstrates that even at pH 8.5 the maleimides react specifically with the 
thiols on the Abs (results not shown). 
After over-night conjugation, immunoliposomes were purified using size exclusion 
chromatography (SEC) (Fig. 7.2). DCIR liposomes, (Fig. 7.2A) and control liposomes (Fig. 7.2B) 
essentially eluted over 2-3 fractions with peak fractions being no. 6 and 7, respectively. Non-
conjugated anti-DCIR Ab eluted in fraction 14-24, non-conjugated control-Ab in fraction 18-28, 
both well separated from the liposomes in the SEC method used. 
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Figure 7.2. SEC purification of DCIR liposomes (A) and control liposomes (B). Lipid concentration was quantified by RhB fluorescence 
(left y-axis), protein concentration was measured using Bradford Plus (right Y-axis). Measured values are relative. Representative of 3 
independent experiments each. 
7.4.2 Characterization of liposomes – size, ξ-potential and polydispersity index (PDI) 
Characterization of the liposomes with respect to size (hydrodynamic diameter) and ξ-potential 
(Table 7.1) showed that all liposomes carried a ξ-potential of -25 to -30 mV and further indicated 
a slight tendency of the DCIR liposomes towards aggregation. As neither m-liposomes nor 
control liposomes displayed this aggregation tendency, we attribute this to interaction mediated 
by the conjugated anti-DCIR Abs. 
As a stability control, we assessed the aggregation tendency over time as evaluated through size 
measurements using DLS (Table 7.1). The measurements show that 48 h post-purification 
aggregation was minimal and after this time point no further aggregation could be detected. 
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 Type of liposome Particle size (nm) PDI ξ-potential (mV) 
A m-liposomes 145.3 ± 3.9 0.12 ± 0.03 -28.6 ± 0.8 
B 
m-liposomes 153.4 ± 2.9 0.13 ± 0.01 -27.1 ± 0.3 
Control liposomes 154.9 ± 1.5 0.22 ± 0.01 -26.9 ± 0.4 
DCIR liposomes 185.1 ± 3.7 0.28 ± 0.01 -25.8 ± 0.7 
C 
m-liposomes 154.2 ± 1.9 0.16 ± 0.01 -26.2 ± 0.6 
Control liposomes 154.8 ± 1.7 0.17 ± 0.04 -26.9 ± 0.5 
DCIR liposomes 179.4 ± 1.9 0.19 ± 0.01 -26.6 ± 1.0 
 
Table 7.1. DLS measurements of size, ξ-potential and polydispersity index (PDI). Size and PDI was measured in 10 mM Hepes, 150 
mM NaCl, pH 7.4. ξ-potential was measured in 300 mM glucose, pH 7.4. A. Measured after extrusion and acclimatization to RT; B. 
Measured after 48 h of storage at 5°C and acclimatization to RT; C. Measured after 72 h of storage at 5°C and acclimatization to RT. 
Values are mean ± S.E.M (n=3). 
7.4.3 Characterization of liposome preparations 
The preparations of m-liposomes, control liposomes and DCIR liposomes were characterized 
with respect to lipid concentration, number of Abs per liposome, concentration of TMX-202 and 
efficiency of conjugation (Table 7.2). In order for immunoliposomes to efficiently target 
leukocyte subsets, on average 40 Abs per liposome has been reported as sufficient156, a criterion 
that our conjugation procedure met for both control and DCIR liposomes. Further, as the m-
liposomes were formulated with 5 mole% TMX-202, a minor but acceptable loss of agonist 
occurred during the conjugation and purification procedure, resulting in a retrieval percentage 
of 90 for control liposomes and 88 for DCIR liposomes of the TMX-202 originally formulated into 
the m-liposomes. Finally, the preparation procedure resulted in a conjugation efficiency of 59% 
and 67% for control liposomes and DCIR liposomes, respectively. 
Type of liposome Lipid Concentration 
(mM) 
Ab per 
liposome 
Conjugation 
efficiency (%) 
TMX-202 conc. 
(µM) 
Mole% of 
TMX-202 
m-liposomes 15.1 ± 0.4 NA NA 770 ± 19.1 5.1 
Control liposomes 1.2 ± 0.1 76 59 55.4 ± 2.8 4.6 
DCIR liposomes 1.2 ± 0.1 68 67 54.0 ± 3.5 4.5 
 
Table 7.2. Characterization of liposome preparations. Lipid concentration was measured by ICPMS (triplicates). Ab concentration was 
measured by Coomassie Plus assay using BGG as standard (triplicates). TMX-202 content was measured by quantitation of 
absorbance at 293 nm after HPLC separation (duplicates). Ab per liposome was calculated as described in the methods section. 
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7.4.4 Liposome association to peripheral blood mononuclear cell (PBMC) subsets 
To establish the targeting properties of the liposomes, a gating strategy was devised, which 
could identify monocytes, mDCs, pDCs and a population comprising of T, B and NK cells 
(Supplementary Fig. 7.1). The gating strategy produced the following PBMC subset percentages: 
13.2% monocytes, 0.8% mDCs and 0.9% pDCs. We incubated PBMCs with liposomes 
corresponding to TMX-202 concentrations of 1 and 10 µM and analyzed the PBMC subsets for 
Rhodamine B (RhB) signal. We found that the DCIR liposomes preferentially associated to 
monocytes, mDCs and pDCs over the combined population of T, B, and NK cells (Fig. 7.3, p < 
0.005). 
 
Figure 7.3. DCIR liposomes associate preferentially to monocytes, mDCs and pDCs. PBMCs were incubated with DCIR liposomes for 1 
h with rotation at liposome concentrations corresponding to 10 µM TMX-202 (clear bars) or 1 µM TMX-202 (shaded bars), and 
association to PBMC subsets was analyzed by flow cytometry. *** p < 0,0001, * p < 0,005, t-test. n = 9. Error bars = S.E.M.  
At 10 µM TMX-202 concentration, the targeting resulted in 84% and 59% RhB positive 
monocytes and mDCs, respectively, whereas the more physiologically relevant agonist 
concentration of 1 µM resulted in 44% and 39% RhB positive monocytes and mDCs (Fig. 7.3). 
While the preferential targeting of pDCs was also significant, it was substantially lower than 
observed for the monocytes and mDCs with the 10 µM TMX-202 concentration causing 14% of 
the pDCs to be RhB positive, and 1 µM agonist concentration resulting in only 4% RhB positive 
pDCs. The T, B, and NK cell population were only 1 and 0.5% RhB positive at 10 and 1 µM TMX-
202, respectively, indicating very limited association of the DCIR liposomes to these cells. As 
monocytes, mDCs and pDCs all perform pinocytosis and are able to present internalized 
antigen135,212,213, some unspecific uptake of the control liposomes was expected, although the 
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observed level was higher than expected (Fig. 7.4). Because this investigation of liposome 
association to PBMCs used normalization to TMX-202 concentration rather than lipid 
concentration and the mole% of TMX-202 is slightly higher for the m-liposomes than for the 
control liposomes (Table 7.2), PBMCs incubated with m-liposomes were exposed to slightly 
lower lipid concentrations than the PBMCs incubated with control liposomes. Still, the 
differences in unspecific association of control liposomes and m-liposomes by particularly the 
monocytes and mDCs at the 10 µM concentration (Fig. 7.4A and B) suggest that part of the 
association of the control liposomes could be mediated by the conjugated Ab. Together, the 
data in Figure 7.3 and 7.4 demonstrate that the DCIR liposomes efficiently and preferentially 
targeted monocytes and mDCs and also showed some association to pDCs. 
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Figure 7.4. Association of DCIR liposomes, control liposomes and m-liposomes to PBMC subsets. A. Association to monocytes; B. 
Association to mDCs; C. Association to pDCs; D. Association to B, T, and NK cells. PBMCs were incubated with DCIR liposomes (DCIR), 
control liposomes (Control), m-liposomes (m-lip) or HBS for 1 h with rotation at liposome concentrations corresponding to 10 µM 
TMX-202 (clear bars) or 1 µM TMX-202 (shaded bars), and association to PBMC subsets was analyzed by flow cytometry. *** p < 
0.0001, ** p < 0.0005, * p < 0.005, t-test. n = 9. Error bars = S.E.M. 
7.4.5 Cytokine secretion from in vitro stimulated PBMCs 
As the DCIR liposomes associated differentially to PBMC subsets, we wished to examine the 
impact of targeted delivery of the TLR7 agonist with respect to activation of the targeted cells, as 
evaluated through measurement of cytokine secretion to the supernatant. PBMCs were 
incubated with DCIR liposomes, control liposomes, free agonist or HBS at a TMX-202 
concentration of 1 µM. The PBMCs were then washed and cultured for 5 days, and the culture 
supernatants analyzed for the secretion of selected cytokines indicative of subset activation on 
each day. 
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Figure 7.5. Cytokine secretion into the culture supernatants on day 1-5. A. IFNα, B. IL-12p70, C. IFNγ, D. TNFα, E. IL-10, F. IL-6. PBMCs 
were incubated with DCIR liposomes (DCIR), control liposomes (Control), free agonist (TMX) or HBS for 1h with rotation at 
concentrations corresponding to 1 µM TMX-202, washed and cultured for 1-5 days. Cell-free supernatants were collected and 
cytokine secretion was measured by ELISA. *** p < 0.0001, one-way ANOVA. n = 9. Error bars = S.E.M.  
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In vivo, pDCs are the principal source of IFNα214, which is a cytokine associated with potent 
cancer-inhibition134,215,216. Further, pDCs have been shown to secrete IFNα when stimulated via 
TLR7 in vitro217, and we therefore analyzed the culture supernatants for IFNα2a (Fig. 7.5A). We 
found that the targeted liposomal delivery of TMX-202 significantly increased the amounts of 
secreted IFNα2a (p < 0.0001) compared to the controls. The cytokine levels for PBMCs 
stimulated with DCIR liposomes were on average 7 fold higher than for PBMCs incubated with 
control liposomes and 28 fold higher than for PBMCs incubated with non-liposomal TMX-202, 
with the IFNα2a-leves detectable from the latter being close to the detection limit of our assay. 
Additionally, it is notable that the cytokine levels remained constant throughout the 5 days of 
culture. 
IL-12p70 is another cytokine which is associated with strong antitumor effects218 and is known to 
be secreted, when PBMCs are stimulated with TLR7-specific agonists164,219. To evaluate whether 
our targeting strategy improved the ability of TMX-202 to induce IL-12p70 secretion, we 
measured IL-12p70 in the culture supernatants (Fig. 7.5B) and were able to demonstrate a 
significantly increased secretion compared to both non-liposomal TMX-202 and control 
liposomes (p < 0.0001). In contrast to IFNα, a gradual reduction of IL-12p70 supernatant levels 
was observable from day 1 to 5, although it didn’t reach statistical significance. The increased 
secretion of IL-12p70 indicates activation of monocytes and/or mDCs, as these subsets (among 
PBMCs) are known to the primary sources of this cytokine130. 
As the targeted delivery of TMX-202 resulted in increased IL-12p70 secretion and IL-12p70 is 
known to be a potent inducer of IFNγ production from NK and T cells130, we wanted to know if 
the increased potency would impact the induction of IFNγ secretion (Fig. 7.5C). We observed 
that free (non-liposomal) TMX-202 was able to induce relatively low amounts of IFNγ, namely 68 
pg/mL on day 1 climbing to 434 pg/mL on day 5. In contrast, incubation with DCIR liposomes 
induced secretion of significantly larger amounts of IFNγ into the supernatant (p < 0.0001), the 
IFNγ levels ranging from 5731 pg/mL on day 1 and climbing to 39 ng/mL on day 4 and 5. The 
temporal profile of the IFNγ levels in the supernatant displayed a clear and significant (p < 
0.0005) increasing trend from day 1 to day 4, where after the level remained constant. 
To further examine the monocyte activation indicated by IL-12p70 secretion, we measured the 
increase in IL-10 and TNFα protein in the culture supernatant, as both these cytokines are 
potently secreted by stimulated monocytes220,221 (Fig. 7.5D and E). Targeted delivery of the TLR7 
agonist resulted in a 3 fold increase of TNFα secretion compared to control liposomes and a 12 
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fold increase compared to treatment with the free agonist (Fig. 7.5D, p < 0.0001). Support for 
the potent activation of monocytes also comes from the secretion of the immunosuppressive IL-
10220 (Fig. 7.5E), where the day 1 protein levels for PBMCs stimulated with DCIR liposomes were 
4 and 30 fold higher than the protein levels for PBMCs incubated with control liposomes and 
free agonist, respectively (P < 0.0001). Interestingly, where the cytokine levels of the pro-
inflammatory TNFα remained essentially unchanged from day 1 to day 5, the IL-10 protein levels 
waned significantly over time (P < 0.005) and on day 4 the protein levels are reduced to 
approximately one third of the peak level on day 2. 
Finally, we evaluated the IL-6 secretion to the culture supernatants (Fig. 7.5F). IL-6 is produced 
by many different cell types including monocytes and T cells, and can be interpreted as a general 
measure of pro-inflammatory response. The DCIR liposomes induced high levels of IL-6 secretion 
compared to free TMX-202 (p < 0.0001); however, so did the control liposomes (p < 0.0001). 
Similar to IFNα2a and TNFα, neither increase nor decline in the measured protein levels could be 
detected over the 5 days of culture.  
Combined, the cytokine measurements demonstrate that the DCIR-mediated targeted delivery 
increased the efficiency of TMX-202 at inducing a pro-inflammatory response, and the data are 
congruent with the activation of monocytes, mDCs and pDCs. Crucially, the increased cytokine 
secretion comprised IFNα, IL-12p70 and IFNγ, which are associated with antitumor immune 
responses based on NK and CD8+ T-cell mediated killing of malignant cells and tumor suppressive 
activity by tumor infiltrating macrophages and DCs216,218,222,223. 
  
7.5 Discussion 
Several studies indicate that dendritic cells, macrophages and T cells are present in the tumor 
tissues in substantial numbers but become polarized towards an inactive phenotype due to the 
immunosuppressive tumor microenvironment112,224. Accordingly, a major goal of cancer 
immunotherapy is to provide activated leukocytes to the tumor tissues through direct activation 
of leukocyte subsets and/or re-polarization of the tumor microenvironment. However, attempts 
to activate tumor infiltrating antigen-presenting cells, macrophages and T cells through systemic 
administration of recombinant cytokines or IRMs such as TLR agonists have had limited success. 
Challenges include dose-limiting toxicity of the compounds, and the fact that systemic presence 
of pro-inflammatory cytokines can result in sepsis-like immune responses168. 
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We have developed a delivery platform, which targets selected leukocyte subsets in the 
bloodstream, by conjugation of a monoclonal anti-DCIR antibody to stealth-type liposomes 
(saturated lipids, 30 mole% cholesterol, 5 mole% PEGylated lipid). The stealth formulation was 
selected to achieve good circulation properties for future in vivo studies and applications as well 
as ensuring that cell association was mediated by the Ab-antigen interaction and not unspecific 
uptake179,225. Our data, which show that the DCIR liposomes associate to a large fraction of the 
monocytes and mDCs as well as a small fraction of the pDCs (Fig. 7.3), are in agreement with the 
reported expression of DCIR, which shows high expression on monocytes and mDCs and lower 
expression on pDCs and B cells204. The very small RhB signal in the T, B and NK cell population is 
most likely due to the DCIR expression on B-cells, which make up 5 - 20 % of the T, B and NK cell 
population226. A more efficient targeting of the pDCs would likely be achievable through 
conjugation of an Ab against BDCA-2 (CD303), which is highly and exclusively expressed on pDCs 
(as well as internalized upon ligand binding)186,227, but this would sacrifice the specific association 
to monocytes and mDCs.  
The control liposomes also showed considerable association to the PBMC subsets (Fig. 7.4). 
Some unspecific uptake due to pinocytosis was expected in spite of the PEGylation of the 
liposomes228. However, as comparison with the uptake of non-Ab conjugated liposomes reveals 
significantly higher uptake of the control liposomes, we conclude that a substantial part of the 
unspecific internalization is mediated by the conjugated Ab. This mediation is probably due to 
the recognition of the murine Fc region by human Fc-receptors. While the conserved nature of 
antibodies across species suggests that this is a possibility, the experimental evidence is 
incomplete229–232. However, two studies have indicated that monocytes in particular are able to 
recognize murine IgG1-Fc230,231, which is the Ab subtype used for this study. 
If a large fraction of the unspecific interaction is caused by recognition of murine Fc, one way to 
eliminate this would be the use of an antibody fragment. Preferably such a fragment should be 
humanized and expressed recombinantly in a way that eliminates the need for the non-specific 
thiolation using Traut’s reagent, which potentially results in thiolation in the antigen recognizing 
part of a fraction of the antibodies, thus rendering them non-functional. Omitting the thiolation 
procedure would also be advantageous as it would allow the fast progress from hydration and 
extrusion of the maleimide-functionalized liposomes to conjugation with the antibody, thus 
minimizing the time wherein the maleimide functional group potentially undergoes degradation. 
We and others209 have observed that degradation of maleimide is a source of variability and 
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diminished yield. Accordingly, minimizing the time from hydration to conjugation, especially in 
buffers with pH above 6.5, is likely to improve yield and reproducibility. 
To functionally activate the targeted cells, we formulated the liposomes with a potent and 
specific TLR7 agonist, TMX-202171–173, which integrated into the control and DCIR liposomes to a 
similar extent (Table 7.2). As TLR7 is located in the endosomes and DCIR is internalized upon 
ligand binding204, the use of DCIR as targeting ligand is a rational choice for facilitation of this 
receptor-agonist interaction.  
To evaluate the activation of monocytes, mDCs and pDCs, we stimulated PBMCs and measured 
cytokines, which were indicative of activation of monocytes, mDCs or pDCs and/or were 
associated with important antitumor activity. Overall, our study demonstrates that targeting of 
TMX-202 to monocytes, mDCs and pDCs significantly increased the potency of TMX-202 with 
respect to induction of a pro-inflammatory cytokine response compared to the free drug (Fig. 
7.5). As the selected cytokines are primarily produced by a limited subset of cells, we may form 
tentative conclusions about the producer cells, even if a correlation analysis did not reach 
statistical significance. 
TLR7-induced secretion of IFNα has been shown to be highly pDC-dependent164,217,219,233. 
Therefore, our results, which demonstrate a substantially increased IFNα secretion with 
relatively limited targeting to pDCs, are evidence of the inducibility of the pDCs and their 
synthetic and secretory capacity, as well as the power of even low levels of targeting compared 
to non-targeted delivery (Fig. 7.3, 7.4 and 7.5A). Further, the presented data suggest that IFNα-
therapy based on the presented platform could represent a significant improvement compared 
to the current therapeutic approach of administering recombinant IFNα intravenously. The 
relatively low absolute protein levels shown here are due to the sub-type specific assay, which 
only measures IFNα2a. However, the work of Birmachu and collegues234 indicates that IFNα2a is 
approximately averagely expressed compared to the other 12 IFNα subtypes when stimulating 
pDCs or PBMCs through TLR7. Therefore, as it is unlikely that each particular TLR7-specific 
agonist has its own distinct expression pattern of IFNα subtypes, IFNα2a may be considered 
indicative of the relative expression levels of all IFNα subtypes. Apart from the ability to secrete 
IFNα, pDCs are also emerging as important in tumor immunology because of their putative 
ability to cross-present ingested antigen134,213. Thus, while the percentage of cells which 
associate with the DCIR liposomes is quite low, these activated pDCs may still make a deciding 
difference in the therapeutic setting. 
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The increased secretion of TNFα and IL-10 as a result of incubation with DCIR liposomes (Fig. 
7.5D and E) indicate activation of monocytes, which are generally accepted to be a primary 
source of these cytokines118. T and NK cells are also capable of TNFα secretion, but they do not 
express DCIR, and a recent study demonstrated that even relatively weak T cell activation as a 
result of TLR7-mediated stimulus required prolonged incubation of purified CD4+ T cells with the 
agonist. Thus the monocytes are the most likely source of TNFα.  
Activation of monocytes is further supported by the detection of secreted IL-12p70 in the 
culture supernatants (Fig. 7.5B). However, as mDCs are considered equally capable of secreting 
IL-12p70130,218,219 and both monocytes and mDCs are TLR7 positive157,197, we are not able to 
determine the accurate cellular origin of the secreted IL-12p70 based on the present data. 
The observation that IL-12p70 is most highly secreted on day 1 is congruent with a primary 
response from directly stimulated cells. In contrast, IFNγ levels increase over 4 days showing 
almost 4 fold higher levels on day 4 compared to day 1 (Fig. 7.5C). The buildup supports that the 
IFNγ secretion is a reaction from T and NK cells to IL-12p70. However, the day 1 levels are also 
very high, indicating either a very fast initial response from T and NK cells or that the IFNγ may – 
at least in part – also be produced as a primary response. While gene expression analyses have 
indicated that CD4+ T cells express low levels of TLR7235 and react to prolonged stimulation with 
Resiquimod (a TLR7/8 agonist) by secretion of IFNγ236, T cells are DCIR negative189 and thus 
unlikely to produce large amounts on IFNγ as a direct reaction to the DCIR liposomes. However, 
recently B cells and mDCs have also been shown to be able to produce IFNγ131,237,238, although 
the protein levels and functional significance remain to be determined. It is conceivable that 
under these conditions either or both of these subsets contribute to the high initial IFNγ-levels. 
Irrespective of the cellular source, IFNγ secretion is potently induced which is highly attractive in 
a cancer immunotherapeutic setting, as IFNγ together with IFNα and IL-12p70 are viewed as 
indicative of an immune response dominated by cytotoxic T lymphocytes and instrumental in re-
polarizing immune cells already present in the tumor tissues131. 
Finally, incubation of PBMCs with DCIR liposomes resulted in increased IL-6 secretion compared 
to incubation with free TMX-202. As the major sources of IL-6 are monocytes/macrophages and 
T cells, and the latter are DCIR negative, this supports monocyte activation due to treatment 
with the DCIR liposomes. However, incubation with control liposomes also induced substantial 
IL-6 secretion (Fig. 7.5F). The reason for this is presently unclear, but could be related to the 
detailed balance of the producing cells and their susceptibility to uptake of the liposomes 
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through association with the Fc part of the conjugated Abs. Elucidation of this phenomenon 
requires further experiments to clearly establish the cellular source of the secreted IL-6. This 
could be compared to the secretion of IL-10 and TNFα, which in our system are also primarily 
synthesized by monocytes, but are induced much less by the control liposomes. 
An attractive therapeutic mechanism of the DCIR liposomes in vivo would be the activation of 
the target cells in the bloodstream followed by infiltration of the tumor tissues and cytokine 
secretion from the activated immune cells in the tumor tissues. A minimal requirement for this 
to be possible is a long-lasting induction of cytokine secretion. To investigate the temporal 
durability of the activation, we therefore measured the cytokine levels for 5 consecutive days 
(Fig. 7.5). In the light of a cell culture with a very high ratio of responder-to-producer cells, it is 
reasonable to assume that when cytokine levels are constant, as seen for IFNα2a and IL-6, some 
level of daily synthesis is likely to have taken place. In addition, the gradual increase in IFNγ 
secretion unequivocally demonstrates freshly secreted IFNγ for each day of culture, while no 
conclusions can be drawn regarding the temporal aspect of cytokine secretion based on these 
data for TNFα, IL-12p70 and IL-10.   
On this premise, we suggest that our approach could result in differentially increased levels of 
IFNα, IFNγ, and IL-6 in the tissues rather than systemically, with the potential to re-polarize the 
tumor microenvironment and eliminate some of the challenges faced by current therapies based 
on systemic administration of cytokines and TLR agonists. Compared to the current practice of 
intravenous administration of recombinant IFNα, IFNα produced by activated pDCs after 
infiltration into the tumor tissues could result in a higher effective dose at the target site and 
lower systemic toxicity as well as comprising all subtypes and not just one recombinant form239.  
In conclusion, we have developed a platform for targeted delivery to monocytes, mDCs and 
pDCs. Using this platform to deliver a TLR7 agonist, we demonstrate that we are able to activate 
the target cells and improve the ability of the agonist to induce the secretion of key pro-
inflammatory cytokines, IL-12p70, IFNγ and IFNα, all considered highly important in obtaining an 
efficient antitumor immune response mediated by CD8+ T cells and NK cells. We hypothesize 
that the strategy of targeting leukocyte subsets in the circulation might be able to supply 
activated immune cells to the tumor tissues. Further, this strategy may be a way to achieve 
secretion of anti-cancer cytokines in the tumor tissues, which may be able to re-polarize the 
tumor microenvironment and thus facilitate tumor elimination. We envision the use of this 
therapeutic strategy either as adjuvant therapy after surgical removal of accessible tumors, as is 
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currently the case for the therapeutic use of recombinant IFNα, or in combination with other 
therapeutic modalities. A recent study demonstrated the benefits of combining systemic 
delivery of a TLR7 agonist with radiotherapy in a mouse lymphoma model240, and our delivery 
platform could be a way to enhance the potency of the TLR7-mediated stimulation and/or 
reduce the side-effects of systemic induction of cytokine expression. 
 
 
85 
 
Project II   
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8 Concluding remarks on Project II 
The results of project II, which are presented in the article draft entitled “Activation of dendritic 
cells and monocytes by targeted delivery of a TLR7 agonist” demonstrate that we succeeded in 
designing a liposomal delivery platform capable of preferential targeting of the monocytes and 
DCs by post-functionalizing liposomes with Abs against DCIR. Further, the results show that 
formulation of a TLR7 agonist into the immunoliposomes produced a system which was highly 
capable of activating monocytes, mDCs and pDCs in vitro. Incubation of PBMCs with the DCIR 
liposomes resulted in secretion of pro-inflammatory cytokines, which have been associated 
positively with the development of cancer immunity. Finally, Project II demonstrates that the 
targeted delivery of the TLR7 agonist dramatically increased the potency of TMX-202 compared 
to the non-liposomal formulation.  
While the presented results demonstrate the power of targeted delivery of TMX-202, several 
opportunities exist for providing a clearer and more nuanced picture of the effects. A first step 
would be to assess the targeting properties of the DCIR liposomes in whole blood to closer 
imitate systemic administration and investigate complement activation by the liposomes. To 
more accurately establish, which of the targeted (or non-targeted) subsets is responsible for the 
synthesis and secretion of each of the cytokines, such a detailed investigation should include 
intracellular flow cytometry on in vitro stimulated PBMCs to investigate the synthetic activity of 
the immune cell subsets. Further, this should be combined with in vitro stimulation of purified 
cells (e.g. purified monocytes) to establish, which of the synthetically active subsets actually 
secrete each of the cytokines and in what amounts. Finally, a more nuanced picture of the 
cellular activation could be obtained by monitoring of up- or down-regulation of cell-surface 
molecules indicative of subset activation. 
While the results demonstrate that efficient targeting of the monocytes and dendritic cells are 
achieved, the immunoliposomal delivery platform also represents interesting opportunities for 
improvement. Currently, insufficient data is available regarding targeting of liposomes to cells in 
the bloodstream. It is for instance unclear how many Abs per liposome are required to obtain 
efficient targeting. As the Abs represent a source of unwanted, non-specific interaction, the 
number of Abs displayed on the liposomes should be minimized. Further, it might be attractive 
to use Ab fragments rather than whole Abs. For instance, the use of recombinantly expressed 
Ab-fragments could tailor the targeting Ab fragment to maleimide-mediated liposome 
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conjugation, thus making comparison of different Ab surface densities more accessible. 
Employing the post-insertion procedure would further contribute to the accessibility of such 
studies and might also reduce loss of Ab.  
Finally, the current in vitro data should be supplemented with in vivo studies, for instance in 
mice. However, this will require switching Ab to one that recognizes the murine equivalent of 
human DCIR. Further, such in vivo studies should take into account that although DCIR is also 
expressed in murine monocytes, DCs and B cells241, the details of the expression pattern may 
differ and Ab binding of murine DCIR may have additional consequences not associated with 
ligation of human DCIR. 
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9 Final concluding remarks and perspectives 
This thesis is concerned with investigation of gene silencing and immunotherapy. Both are 
strategies that - in an envisioned therapeutic setting - promise high specificity through the 
exploitation of endogenous mechanisms intended for regulation of gene expression and immune 
defense, respectively. 
The study of non-viral siRNA delivery focused on strengthening the understanding of polyplex 
interaction with the target cells as well as their intracellular processing. Increased understanding 
is pivotal in order to bring non-viral siRNA delivery closer to the clinic, and a fitting example of 
this is our incomplete understanding of the endosomal escape. 
The presented results confirm that the use of PEI “off the shelf” for siRNA delivery has no future. 
Importantly, the study demonstrates the importance of the bound and the free fraction of 
polycation for siRNA delivery – in the absence of co-delivered free fraction, both conventional 
PEI and lipid conjugated PEI are ineffective delivery agents. Further, lipid conjugation in itself did 
not improve the delivery properties or the cytotoxicity profile of PEI, and consequently other, 
more elaborate modifications of PEI are required to provide the significant improvements 
necessary to make this polymer a potential part of an efficient vector for non-viral siRNA 
delivery. 
Section 4 of this thesis briefly describes one such hypothetical modification, namely the 
encapsulation of the polyplex, bound and free fraction, in a delivery vehicle. However, as also 
described, such an approach is probably overly complicated compared to lipofection. 
Our observations regarding the efficiency of lipofection are to some extent reflected in the 
delivery platforms, which are currently attracting the most interest commercially. So far, the 
only polycation-based delivery platform to show substantial promise has been the Rondel™ 
delivery technology developed by Mark Davis and colleagues at Caltech80,242. The Rondel™ 
platform is based on a cyclodextrin-containing polymer and showed promising initial results in 
phase I trials against melanoma, but further development was discontinued due to the 
emergence of adverse events. 
However, the current trend in non-viral RNAi therapy is a move towards lipofection243 and a 
number of early-stage cancer indications are being pursued, many of them using the SNALP 
technology developed by Pieter Cullis’ group at UBC, Canada244. However, as only one of these 
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efforts has so far reached stage II clinical trials, cancer treatment based on non-viral delivery of 
siRNA still has some way to go before realizing the potential envisioned at the time of its 
discovery. 
On the other hand, the research into cancer immunotherapy is starting to produce positive 
results. With the introduction of cytokine therapy, the use of the TLR7-based Imiquimod for 
treatment of melanoma, and – notably – the approval of the checkpoint blockers, the world is 
seeing the emergence of therapies, which are able to assist the immune system in its effort to 
eliminate the malignant cells. 
A major hurdle to the use of systemically administered immune response modifiers such as TLR 
agonists has been the risk of introducing an uncontrolled systemic immune response. While the 
presented platform does not specifically target the tumor tissues, the increased potency it offers 
by directing the agonist to DCs and macrophages could provide higher effectivity, which could 
lower the required administrated dose, thus lowering the risk and/or severity of the induced 
side-effects. 
As recombinant IFNα is already used in the clinic, we find it particularly interesting that even a 
modest targeting of the pDCs results in a dramatically increased concentration of IFNα2a in the 
culture supernatants compared to the non-targeted control. It would be highly interesting to 
investigate the level of activation and IFNα secretion achievable by efficient targeting specifically 
to the pDCs of the TLR7 agonist, as well as investigate the release of all the IFNα subtypes. 
Finally, as a measure of the potential therapeutic applicability, the effect on tumor progression 
in an animal model would complete the picture. 
Interestingly, the presented data indicate that for some of the cytokines at least part of the 
secretory activity is sustained over several days. We therefore hypothesize, that our strategy of 
activating or preconditioning the DCs and macrophages in the blood could be an elegant way of 
increasing the concentration of pro-inflammatory anti-cancer cytokines in the tumor 
microenvironment. The resulting increased concentration of pro-inflammatory cytokines with 
antitumorigenic effects might be able to drive the re-polarization of the tumor 
microenvironment. Currently, this remains highly speculative, but the temporal profile of the 
cytokine secretion observed in Project II certainly warrants further examination. The concept of 
achieving cytokine secretion in the tumor tissues by activating cells in the blood rather than in 
the tumor tissue is highly attractive because it circumvents the need for passive accumulation of 
nanoparticles in the tumor tissues by the EPR effect. While the EPR effect is present in certain 
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cancer forms without a doubt, it is equally clear that in other cancer types it is absent or 
insufficiently pronounced to ensure adequate accumulation. The described approach could thus 
enable nanoparticle based treatment of such cancers while simultaneously limit the induction of 
cytokine syndrome associated with systemically administrated IRMs. 
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